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Abstract
IMPACT OF IMMUNOTHERAPY ON THE SURVIVAL OF PANCREATIC CANCER PATIENTS
Saber Ali Amin, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor and co-supervisor: Jane Meza, Ph.D., and Chi Lin, MD, Ph.D.
Pancreatic adenocarcinoma (PDAC) represents 7.2% of all cancer deaths, and by 2030, it will
become the second leading cause of death due to cancer. The median overall survival (OS) is 1723 months in resectable and 4-6 months in metastatic PC [8-9]. The 5-year survival of resectable
PC is 22%, and unresectable PC is 8%. A majority of patients treated with standard treatments
such as surgery, chemotherapy, and radiation therapy eventually succumb to the disease due to
widespread micrometastases at the time of diagnosis. Due to the minimal effect of the current
treatments, novel treatment strategies such as immunotherapeutics have been proposed.
Immunotherapy has shown excellent efficacy in many other malignancies, but its role in the
survival of PC patients is unclear.
The objectives of this dissertation were to investigate the impact of immunotherapy, including
the sequence of treatments on the OS of PC patients stratified by definitive surgery of the
pancreatic tumor. Data from the National Cancer Database was used to address these
objectives. In this study, immunotherapy was associated with improved OS compared to no
immunotherapy in both patients who received definitive surgery of the pancreatic tumor and
patients who did not undergo surgery. In the surgery group, patients who received

chemotherapy plus immunotherapy or chemoradiation plus immunotherapy had better OS
compared to their counterparts without immunotherapy. In the no surgery group, patients who
received chemoradiation plus immunotherapy had better OS compared to patients who
received chemoradiation without immunotherapy. There was no significant difference in the OS
of patients who started immunotherapy 31-90 days before chemotherapy, patients who started
immunotherapy 91-180 days before chemotherapy, and patients who started chemotherapy
and immunotherapy within 30 days of each other. There was also no significant difference in the
OS of patients who started RT> 30 days before the start of immunotherapy, patients who
started immunotherapy > 30 days before RT, and patients who started RT and immunotherapy
within 30 days of each other. There was no significant difference in the OS of patients who
received neoadjuvant immunotherapy and patients who received adjuvant immunotherapy. The
study also highlighted the need for improving access to novel treatments as patients with older
age, Black race, living in the rural areas, living in the areas with low education level, and
diagnosis before 2011 were less likely to receive immunotherapy compared to their
counterparts. The findings of the current study warrant future clinical trials of immunotherapy
in PDAC patients.
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CHAPTER 1
INTRODUCTION
IMMUNOTHERAPY IN PANCREATIC CANCER
Epidemiology and Treatment Challenges
The human pancreas is a large solitary retroperitoneal organ located behind the
stomach in the upper abdomen and surrounded by small intestine, liver, and spleen.1 The
pancreas is mainly composed of two portions, the exocrine pancreas, and the endocrine
pancreas.1,2 The exocrine pancreas makes more than 95% of the pancreatic mass and is
responsible for producing enzymes that are essential for food digestion.2 The endocrine cells
make hormones such as insulin and glucagon which have a pivotal role in controlling blood
glucose level.2
The majority of pancreatic tumors arise from the exocrine portion of the pancreas and
resemble like pancreatic duct and are therefore called pancreatic ductal adenocarcinoma
(PDAC).2 The tumors arising from the endocrine portion are less common and are called
pancreatic neuroendocrine tumors.2 More than 85% of pancreatic cancers are PDAC.3
Pancreatic adenocarcinoma is the seventh leading cause of global cancer deaths4, and the third
leading cause of cancer deaths in the USA.5 Pancreatic adenocarcinoma was ranked the 11th
most common cancer globally, accounting for 458,918 new cases and 432,242 deaths
worldwide.4 Each year, more than 53,000 people in the U.S. are diagnosed with PDAC, while
more than 34,000 people die from it.6 Pancreatic cancer represents 3.2% of all cancer cases, but
it is responsible for 7.2% of all cancer deaths in the United States.6 It is predicted that by 2030,
PDACC will become the second leading cause of cancer death.7 The cause of PDAC is complex
and multifactorial, but certain factors are associated with the increased risk of PDAC.8 Smoking
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cigarettes is the most important and established risk factors of PC, which increases the risk of
PDACC by up to 75%.9,10 Advanced age, male gender, Black race, family history, and obesity are
some other predictors of PDAC.11-13
Due to the lack of early detection methods, lack of signs and symptoms, late
presentation, disease heterogeneity, and treatment resistance, PDAC is challenging to treat.14
More than 80% of patients present with locally advanced (non-resectable) or metastatic PDAC,
while only 20% present with resectable PDAC.15 The five-year survival of PDAC is 8% and 22% in
non-resectable and resectable patients.16,17 Surgery is the gold standard and only curative
treatment improving overall survival (OS) by ten months compared to no surgery, but more than
80% of the operable patients who undergo curative-intent surgery experience relapse.18,19
Chemotherapy makes up the backbone of treatment for non-resectable patients, but due to the
chemotherapy-resistant characteristic of PDAC, it only improves OS modestly compared to no
chemotherapy.20-22 In addition to chemotherapy, most of the non-resectable PDAC patients also
receive radiation to enhance local control.23
A majority of patients treated with standard treatments eventually succumb to the
disease due to widespread micrometastases at the time of diagnosis.24 Due to the lack of
significant benefits of the currently available treatments, there is a desperate and urgent need
to develop novel treatment strategies for pancreatic cancer treatment. Immunotherapy is one
of the innovative treatment strategies which has shown great success in the last few years in the
treatment of various malignancies, and it is an area of exploration for the treatment of PDAC.
Cancer and Immune System
Immune evasion is one of the emerging hallmarks of cancer. Cancer development and
progression is associated with the inability of the immune system to eliminate or control the
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growth of cancer cells.25 Cancer cells can evade immune destruction by modulating their cellular
characteristics and, through recruitment and training of the various immune cells and the
production of different cytokines and chemokines, by creating an immunosuppressive tumor
microenvironment.26-28 Immunotherapy considered the fourth pillar of cancer treatment, can
overcome the immunosuppressive and immune evading properties of cancer cells by reducing
the immunomodulatory alterations to cancer cells as well as manipulating the tumor
microenvironment, thus allowing for the detection and destruction of cancer cells.29-31
Immunotherapy in PC
Types of cancer immunotherapies include checkpoint blockade immunotherapy (CBI),
therapeutic cancer vaccines, and non-specific immunotherapies such as cytokines, interleukins,
and interferons.32 Checkpoint blockade immunotherapy (CBI) has been the most widely used
immunotherapy to date, the mechanisms of which primarily rely on alteration of immune cell
checkpoints, which are manipulated by cancer cells to allow for immune evasion.33,34 T-cells
mediate cellular immunity, which is strictly supervised and controlled by a check and balance
system performed through stimulatory and inhibitory receptors.34 The inhibitory receptors are
called immune checkpoints, and their primary role is to maintain self-tolerance and limit tissues
damaged during the immune response against pathogenic invasion.25,34
Checkpoint receptors are expressed on the surface of cytotoxic T-cells in the form of
cytotoxic T lymphocyte-associated 4 (CTLA-4) and on T cells, B cells, natural killer, and dendritic
cells in the form of programmed cell death protein 1 (PD-1).35,36 When activated, these
checkpoint receptors downregulate T-cell activation and effector function.37 Specifically, CTLA-4
binds to B7-1 and B7-2 co-stimulatory molecules on antigen-presenting cells (APCs) and
transmits an inhibitory signal to T-cells, which blocks T-cell activation. PD-1 and its ligands,
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programmed cell death ligand 1 (PD-L1) and PD-L2, impose inhibitory signals on T-cell activation
and proliferation.37-39 Checkpoint blockade immunotherapy can inhibit CTLA-4 and PD-1
pathways and thus functions by negatively regulating the immuno-inhibitory response,
removing the brakes on the immune system.38

Literature Overview
CBI first made inroads in cancer in the setting of metastatic melanoma with ipilimumab
(an anti-CTLA-4) in 2011 and pembrolizumab (anti-PD1) in 2014.40,41 Ipilimumab showed
improved median survival of 10 months (95% CI: 8.0-13.8) and 1-year OS of 46% (95% CI: 37%54%) compared to 6 months (95% CI: 5.5-8.7) median survival and 25% (95% CI: 18%-33%) 1year OS in the comparison arm of a glycol protein gp100 peptide vaccine without ipilimumab.
Pembrolizumab showed improved progression-free survival (HR: 0.46, CI: 0.46 to 0.72; P <0.001)
and 1-year OS of (HR: 0.69; CI, 0.52 to 0.90; P < 0.0036) compared to ipilimumab. Since this
time, the role for immunotherapy has expanded to include advanced melanoma, non-small cell
lung cancer (NSCLC), Hodgkin's lymphoma, head and neck cancer, microsatellite instability-high
cancer, gastric cancer, advanced renal cell cancer, bladder cancer, liver cancer, and Merkel cell
carcinoma.14,42-45
Immunotherapy has not been approved for the treatment of PC but is used in an offlabel setting mostly extrapolating the utility in various other malignancies.42,46,47 However, how
immunotherapy may fit into the treatment paradigms of pancreatic cancer in PC remains
unclear. Immunotherapy has been currently in several clinical trials for PC, but to date, the
results have been negative.42,46,48,49 The findings of previous studies have been summarized
below.
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Checkpoint Inhibitors
The initial trials of the monotherapy with checkpoint inhibitors in PC failed to show any
benefit.50-54 In a total of 4 clinical trials investigating anti-PDL1 antibodies that included PC
patients, results have been mixed with 3 showing no objective response, one showing stable
disease, and one showing a 7% objective response rate with 21% of patient realizing disease
stability. Importantly, however, PC comprised a small cohort of the included patients with the
largest single-trial PC sample size being only having 29 patients. The details are in Table 1.
Synthetic Vaccines
Synthetic vaccines are made of a whole protein or peptide that matches a predetermined antigen to induce T cell response. There have been various large clinical trials
targeting the different immune-related channels, but almost none of them have shown any
meaningful efficacy and improvement in OS. The majority of these trials indicated that the
treatments were safe and tolerated well but failed to improve OS. The trials were not designed
to investigate OS because the majority of them were phase 1 and focused predominantly on the
safety and tolerability of these treatments.
Carcinoembryonic antigen (CEA). The phase 1 trials of the mono vaccination therapy
targeting Carcinoembryonic antigen (CEA), expressed in 90% of the pancreatic adenocarcinoma,
showed that these treatments were well tolerated, and patients had longer OS compared to a
historical control group.55,56 One study of 19 patients with resected or metastatic PC reported
stable disease in 5 of the 19 (37%) patients who were alive at 32 months from the initiation of
the trial including three patients with metastatic PC.55 The second study which included two
phase 1 studies, investigated the safety of PANVAC-VF that contains genes for CEA, mucin-1, and
three costimulatory molecules B7.1, Lymphocyte function-associated Antigen 3 (LFA-3), and

6
Intra-Cellular Adhesion Molecule-1 (ICAM-1).56 Overall, 22 patients with stage III-IV PC were
enrolled in these two studies. No serious adverse event related to the vaccine was reported. The
median OS was 7.9 and 6.3 months, with a one-year survival of 33% and 30%. The median OS in
these studies is longer compared to the anticipated median OS of three months based on
historical controls for metastatic PC.56
Gastrin 17. The trials of mono vaccine therapy in PC that have used gastrin reported
positive immune response.57-59 A randomized, double-blind, placebo-controlled, groupsequential multicenter trial investigated the impact of G17DT (antigastrin immunogen) in PC.57
The study included 145 patients with advanced PC who were not able to take chemotherapy.
The adjusted analysis did not show any difference between the treatment and the placebo
group (HR: 0.75, CI; 0.51-1.10, P = 0.138). In unadjusted analysis, the median survival time was
152 days for G17DT and 82 days in the placebo group (P <0.03). In the study participants, more
than 74% developed anti G17DT, and they had prolonged survival, 176 days compared to the
nonresponders 63 or the placebo 83 days (log-rank test, p < 0.003). The treatment of G17DT was
well tolerated.57
Another phase 2 study included 30 patients with advanced PC and investigated the
antibody response, safety, tolerability, and efficacy of the anti-gastrin-17 or G17DT. In the study,
67% of the participants produced an antibody response. The response was higher in the 200
micrograms 82% compared to 46% in the 100 microgram patients (p <0.01). The median survival
was significantly longer in the antibody responders compared to the nonresponders (217 days
vs. 121 days, p<0.002).58 Another trial that included 394 patients with stage II-IV PC did not
report any benefit of the antigastrin vaccine.59 In this study, the antigastrin vaccine was used in
combination with gemcitabine.59
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Table 1. Studies of checkpoint inhibitors alone or in combination with other cancer treatments in PC
Trial
Brahmer et al.
(2014)51
NCT00729664

Country and eligibility
U.S.A. Age>18, the life
expectancy of >12 weeks,
performance status of <=2,
measurable disease, normal
hepatic and renal tests

Intervention and objective
Single-arm: Anti-PDL1 antibody
Primary objective: Assess the safety and
adverse-event of anti-PD-L1 in advanced
cancer patients. Secondary objective: the
assessment of the antitumor activity and
partial and complete response rate

Sample size
N=207 with advanced
cancers in whom (n=14)
were PC but only seven
evaluated

Result
No objective
responses in PC
patients to date

Royal et al. (2010)50
NCT00112580

U.S.A. Age>18, locally
advanced or metastatic Stage
IV PC, with > 3 months life
expectancy, no surgery, no
concurrent chemo

Single-arm: Anti-CTLA4
Primary outcome measures: Partial and
complete response. Partial response: At
least a 30% reduction in the size of all
measurable lesions. Complete response:
Disappearance of all clinical evidence of
disease

Only PC (N=27), 20
metastatic and 7 were
locally advanced
(unresectable)

Patnaik et al.
(2015)52
KEYNOTE-001

International trial. Age>18,
performance status 1 or 0,
and normal renal and other
organs test. Patients
previously treated with PD-1
and patients with the autoimmune disease were
excluded
U.S.A. Age >18, P.F. of 0 or 1,
histologically confirmed
diagnosis and adequate or
normal functions test.
Patients with auto-immune
diseases, CNS, HI., Hep A, B,
and C were excluded

Anti-PD1 monoclonal antibody
Evaluate the safety, pharmacokinetics,
and pharmacodynamics of
pembrolizumab in patients with
advanced solid tumors. Also, antitumor
activity and maximum tolerated dose

N=30 with solid tumors
PC=1

No acceptable
response rates. A
significantly
delayed
regression of the
tumor was
noticed in one
patient
stable disease
was reported in
the patient

Anti-PDL1, single-arm dose efficacy study
Primary outcome: dose-limiting toxicities,
a maximum tolerated dose of
Atezolizumab, percentage of participants
with adverse events. Secondary outcome:
Objective response rate, progressive
disease, and progression-free survival

Different types of cancers
N=277
PC=5 Only one was
evaluated

Herbst et al.
(2014)53
NCT01375842

No positive results
for PC, as it was
combined to the
category of others
due to sample size

8
Segal et al. (2014)54
NCT 01693562
Current trial

U.S.A. and other countries.
Adequate organ function and
performance status

Anti-PDL1 dose-escalation study
Primary endpoint: safety and tolerability
Secondary: antitumor activity

N=408 advanced solid
tumors
PC=29

Aglietta et al.
(2014)60

Canada. Age>18,
performance status 0 or 1,
normal tests of other organs
and not having auto-immune
diseases and should not have
taken ant-CTLA4 before

Anti-CTLA4, dose-escalation, and
tolerability study of gemcitabine plus
tremelimumab. Primary objective:
Evaluating the safety of tremelimumab
plus gemcitabine. Secondary purposes:
Monitoring for preliminary evidence of
efficacy for the combination and
evaluation of drug pharmacokinetics

N=34 Metastatic PC

U.S.A. Patients with normal
blood and urine tests, P.S. of
0 or 1. No previous
treatments with chemo and
no auto-immune diseases

Combination of gemcitabine and
ipilimumab (CTLA4). Primary outcome:
Dose Limiting Toxicities. Secondary
outcome: overall survival, progressionfree survival, the best overall response

N=13 advanced PC

Response
rate=15% (2/13),
SD=38% (5/13)

U.S.A. multi-center. Age >18
and no use of the treatment
before

Nivolumab With Nab-Paclitaxel Plus or
Minus Gemcitabine (PD1 with two
chemotherapeutic agents). Objectives:
Maximum dose tolerance, OS, disease
control rate, progression-free survival

N=17 locally advanced or
metastatic PC, Arm A=11,
B:6 A: dose-limiting
toxicities, Arm B: assess
the tolerability, efficacy

RR=29% (5/17),
SD=41% (7/17)

NCT00556023

Kircher et al.
(2016)61
NCT01473940

Wainberg et al.
(2017)62
NCT02309177

PS: performance status RR.: response rate SD: stable disease

Disease Control
Rate 21% (6/29)
and objective
response rate of
7% (2/29)
PR: 10.5% (2/19),
SD: 7 patients had
S.D. at week 10.
Only two
completed four
cycles. OS was 7.4
months (95% CI
5.8–9.4) based on
historical data
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Autologous Vaccines. These are cellular-based vaccines in which the patient’s dendritic
cells are isolated and pulsed with a specific antigen and then reinfused back to the patient. The
trials of autologous vaccines of mucin-1 showed mixed results.63-67 A retrospective study of 17
patients of refractory and metastatic PC that used dendritic cell vaccine combined with
activated lymphocyte also reported improved OS.63 The median OS was nine months, which is
longer than the expected survival in these patients. The combination of immunotherapy with
chemotherapy did not show any difference in survival compared to immunotherapy alone.63
Another phase I/II study of mucin-1 dendritic cell vaccine in resected PC also reported
the safety of the vaccine.64 The study, which included 10 PC patients reported 33% OS of five
years [80].64 Another study investigated the efficacy of mucin-dendritic cell and cytotoxic
lymphocyte combination in 20 patients with recurrent and unresectable PC.65 In this study, one
patient had complete remission of lung metastasis, and five had stable disease. The mean
survival time was 9.8 months. The one-, two-, and three-year survival rates were 20%, 10%, and
5%.65
Another study of the mucin-1 transferred dendritic cell vaccine showed an immune
response in the patients, but no survival benefit was observed.66 The study included ten patients
in which more than 90% (9/10) of the patients noticed progress in their disease.66 A study of
adoptive cell transfer mucin-1 vaccine that included 28 patients (8 with unresectable and 20
with resectable PC) reported improved survival.67 The median survival time was five months in
unresectable patients. The median survival time of adjuvant immunotherapy in the resectable
patients was 17.8 months. The 1-, 2- and 3-year survival rates after resection were 83%, 32%,
and 19%, which is better than the surgery alone.67 The details of the vaccine studies in PDAC are
provided in Table 2.
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Table 2. Studies of vaccines alone in PC
Trial

Country and eligibility

Intervention and objective

Sample size

Result

Geynisman et al.
(2013)55
NCT00203892

USA: performance status of
0 or 1, enough organ
functions, no previous
treatment with CEA, no
prior systemic therapy

Phase 1 randomized pilot trial
primary endpoint: determine the dose of
modified CEA peptide (CAP1-6D)/
Montanide/GM-CSF-vaccine to induce an
optimal CD8+ T cell response. Secondary
point: dose-limiting toxicities, progressionfree survival, and median OS

N=23 resectable
and advanced PC,
19 received at
least one dose

SD: 5/19 (37%) and
were alive at 32
months after the
randomization

Schuetz (2005)56
abstract

US A
PC patients with localized
and metastatic cancer

N=22, stage IV
(N=22) stage III
(N=2). There
were two studies

Gilliam et al. (2012)57
KEYNOTE-001

A randomized, double-blind,
placebo-controlled,
international multicenter
trial: PC patients with
Karnofsky performance
score of 60 or higher, the
life expectancy of > 2
months

Primary objective: the safety of PANVACVF, which contains the genes for CEA,
MUC-1, and three costimulatory
molecules (B7.1, LFA-3, and ICAM-1) in 2
viral vectors
Investigated G17DT in patients unsuitable
for or unwilling to take chemotherapy. The
primary objective of this study was to
determine the effect of G17DT versus
placebo on the survival of patients

Median OS in the two
studies was 7.9 and
6.3 months. Oneyear survival was
33% and 30%
No difference in
adjusted analysis
(HR: 0.75, CI; 0.511.10, P = 0.138), but
unadjusted analysis,
the median OS was
152 days for G17DT
and 82 days in the
placebo group (P
<0.03). Those who
developed antiG17DT had 176 days
OS compared to the
nonresponders 63 or
the placebo 83 days
(l P = 0.003)

N=154 with
advanced PC, 79
received G17DT
and 75 placebo
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Brett et al. (2002)58
NCT01375842

UK single-center study

Phase II Study of Anti–Gastrin-17
Antibodies. Patients were recruited to
receive three doses of 100 _g of G17DT on
weeks 0, 2, and 6

N=30 patients
with advanced
PC

Shapiro et al.
(2016)59
Abstract

A randomized, double-blind
trial. Patients with intact
organ function, KPS≥70, and
evaluable or measurable
disease

N=394 patients
with stage II, III,
and IV PC

Nakamura et al.
(2009)63

Japan. A retrospective single
hospital-based study

Patients were randomized 1:1 to
G17DT+Gem or identical matching
placebo+Gem in two strata (disease stage
II+III vs. IV). G17DT/placebo was
administered im at wk 0, 4, 8, and 24;
Gemcitabine (1 g/m2 administered to
subjects in both arms
A retrospective study of comparing
dendritic cell (DC) vaccine plus an injection
of lymphokine-activated killer
lymphocytes (LAK) vs. (LAK) alone

Lepisto et al. (2008)64

USA. Patients > 18 years old)
with surgically resected
pancreatic or biliary tree
cancer within 3-24 months
of study entry

A phase I/II study of a MUC1 peptidepulsed autologous dendritic
cell vaccine as adjuvant therapy in
patients with resected
pancreatic and biliary tumors. Exploratory
safety study

N=10 resectable
PC

N=17 patients
with refractory
and metastatic
PC

Antibody response
was 82% in the
200microgram vs.
46% in the 100
microgram patients
(P=0.01). Median OS
was 217 days vs. 121
days, P<0.002
No positive results.

OS was nine months
in the entire cohort,
nine months in the
DC group, and d 6
months in LAK.
chemo plus
immunotherapy vs.
immunotherapy
alone had the same
OS
The median survival
was 26 months
(range 13-69 months)
for all patients. 33%
were alive after fiveyears
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Kondo et al. (2008)65

Japan. Single hospital-based
study

Objective: Evaluate the efficacy of
combination mucin-dendritic cell and
cytotoxic lymphocyte

N=20 with
resectable or
recurrence PC

One patient had a
complete response. 5
had SD. The mean OS
was 9.8 months. The
one-, two-, and
three-year survival
rates were 20%, 10%,
and 5%

Pecher et al. (2002)66

Germany. Single institutebased trial

A phase I/II clinical trial using human
autologous DC transfected with cDNA of
the human tumor antigen mucin (MUC1).
Objective: Evaluate the safety of the
vaccine, the induced cellular immune
response, and the clinical response

N=10 patients 2
of them were PC

The immunological
response was
reported, but no
benefit in OS was
noticed

Japan. Single institute-based
study

Objective: analyze CTLs stimulated by YPK1 cells and to evaluate the clinical efficacy
of AIT with this type of CTL for
unresectable and resectable PC

N=28, in which 8
had unresectable
PC and 20 had
resectable PC

The median OS was
five months in
unresectable
patients. The 1-, 2and 3-year survival
rates after resection
were 83%, 32%, and
19%, better than
surgery alone. The
median OS time of
adjuvant
immunotherapy in
resectable patients
was 17.8 months

Kawaoka et al.
(2008)67

CEA: carcinoembryonic antigen OS: overall survival

PC=pancreatic cancer
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Vaccines and Chemotherapy Combination
Mucin-1 vaccines
Studies of the combined use of peptide vaccines of mucin-1 with the SmithKline
Beecham adjuvant system (SB-AS) or Incomplete Freund's reported that these treatments were
well tolerated and are safe.68,69 However, these trials did not show benefits in PC patients. The
study of the peptide vaccine of mucin-1 with Incomplete Freund's included nine patients in
which one patient had stable disease, while 7 developed the progressive disease after the
treatment.68 The study that used peptide vaccine of mucin-1 with SB-AS adjuvant enrolled 16
patients with resected or locally advanced PC without prior chemotherapy or radiotherapy.69
The study reported an increase in the peripheral T cells post-vaccination. Out of 15 resectable
PC patients, 13 died, and only two were alive at follow-up of 32 and 61 months. The median
survival time was 12 months, which is comparable with a historic control.69
A study used autologous dendritic cells containing mucin-1 with gemcitabine and S1 in
the 49 recruited metastatic PC.70 The participants either received DC vaccine alone or DC vaccine
plus lymphokine-activated killer (LAK) in combination with gemcitabine and or S1. Out of 49
patients, two had a complete response, five had partial remission, and 10 had stable disease.
Median survival was 360 days, significantly longer than historical control. Patients who received
DC vaccine+LAK in combination with chemotherapy had more prolonged survival than those
who did not receive LAK (396 days vs. 229 days).70
Kras peptide vaccines
A phase I/II study of 38 advanced PC and ten resectable PC, used KRAS peptide vaccines
in combination with Granulocyte-Macrophage Colony-Stimulating Factor.71 Ninety percent of
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the resectable and 32% of the unresectable achieved stable disease. Mean OS was 25.6 months
in the resectable compared to 16.7 months in the historical control. Mean survival time in the
immune responders was significantly longer than the nonresponders (148 days vs. 61 days,
p<0.002).71 Another study of 24 patients with resected PC, used the same combination and
reported a median recurrence-free survival of 8.6 months (CI: 3.0 –19.2), and a median OS of
20.3 months (CI, 11.6–45.3). The median OS was not different in those who received adjuvant
KRAS vaccine and in those who did not.72
A study of 39 KRAS mutated patients with resected PC investigated the efficacy of GI4000, heat-killed recombinant S. cerevisiae plus gemcitabine vs. gemcitabine alone and reported
longer median OS ( 526 days vs. 444 days), more prolonged recurrence-free survival (278 days
vs. 255 days), and higher 1-year survival rate (72% vs. 56%) for the combined arm compared to
gemcitabine alone.73 Another study of 23 patients with resected PC reported a median OS of
27.5 months for the entire cohort and a 5-year survival rate of 29% and 22% in those who
showed an immune response and those who did not.74
Telomerase peptide vaccines
The studies of the telomerase peptide vaccines failed to show any benefit in PC.75-78 One
of the most extensive trials of telomerase vaccine investigated the safety and efficacy of the
vaccine in combination with gemcitabine in locally advanced or metastatic PC in the UK.75 The
trials assigned 1062 patients to chemotherapy, sequential chemoimmunotherapy, and
concurrent chemoimmunotherapy. The median OS was 7.9 months in the chemotherapy group,
6.9 months in the sequential chemoimmunotherapy, and 8.4 months in the concurrent
chemoimmunotherapy group, which was not significantly different from each other. The
addition of the telomerase vaccine to chemotherapy did not improve OS.75
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Two studies that investigated the efficacy of GV1001 in combination with gemcitabine in
metastatic PC and were terminated prematurely as the preliminary analyses did not show any
survival benefit.76,77 The preliminary analysis of one study was based on 174 patients and
another on 178 patients. Only one study of the telomerase peptide vaccine reported survival
benefit.78 Forty-eight patients with unresected PC were enrolled and received telomerase
peptide GV1001 in three dose levels in combination with GM-CSF. The treatment was well
tolerated, with no significant grade three adverse events. Vaccine-related immune response was
noted in 63% of the patients. The intermediate dose group had significantly longer OS compared
to the high and low dose group (8.6 vs. 4.0 vs. 5.1 months). Median survival was significantly
longer in the immune responders compared to the nonresponders (7.2 vs. 2.9 months, p
<0.001).78
GM-CSF vaccines
In phase I trial of GM-CSF enrolled 14 patients with stage I, II, and III of PC79, three
patients had a disease-free survival of 25 months. In another phase II trial of 60 patients with
resectable PC, patients received GM-CSF with chemotherapy or chemoradiation and a median
disease-free survival of 17.3 months (CI, 14.6–22.8), and a median survival of 24.8 months (95%
CI, 21.2–31.6).80 An open-label study with 50 participants of metastatic PC, patients received
GM-CSF alone or in sequence with Cyclophosphamide. The treatments were well tolerated, and
a higher rate of Mesothelin-specific T cell responses was reported in the cohort who received
chemotherapy prior to immunotherapy, but OS was not improved.81 The details of the studies of
vaccines combined with chemotherapy in PC are provided in Table 3.
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Dendritic cells with chemotherapy or radiation therapy
A meta-analysis that included 14 clinical trials, all of which were conducted in China,
investigated the efficacy and safety of dendritic cells–cytokine-induced killer (DC–CIK) cells
immunotherapy in PC.82 The study included 1,088 PC patients and the combination of
immunotherapy and chemotherapy showed higher partial response rate (OR =1.49, 95% CI
=1.06–2.10, P=0.02), higher overall response rate (OR =1.69, 95% CI =1.20–2.38, p <0.003),
higher disease control rate (OR =2.33, 95% CI =1.63–3.33, P,0.001), and low disease progression
rate (OR =0.43, 95% CI =0.30–0.61, p<,0.001) compared to chemotherapy alone.82 The combined
therapy also had higher OS compared to chemotherapy alone with the odds ratio of 1-year OS
(OR =3.61, CI =2.41–5.40, P,0.001) and 3-year OS ( OR =2.65, CI =1.56–4.50, p<0.003).
Another meta-analysis that included 11 trials with a total of 413 PC patients investigated
the efficacy of dendritic cells (DCs), cytokine-induced killer cells (CIKs), natural killer cells (NKs),
lymphokine-activated killer cells (LAKs), and GM-CSF.83 The 1-year OS was 65% in the
immunotherapy arm, which was combined with either radiation therapy or chemotherapy and
45% in the non-immunotherapy arm, which was either radiation therapy or chemotherapy
alone. The 1-year OS was significantly improved in the immunotherapy arm ((OR: 2.95; 95%
CI:1.64–5.31; p< 0.003) compared to the non-immunotherapy arm.83 The 3-year OS rate was 38
for the PC patients receiving immunotherapy, while it was 16% for the controls. The 3-year
survival was significantly improved in patients who received immunotherapy compared to the
control arm (OR: 3.25; CI: 1.37–7.70; p<0.007).83
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Table 3. Studies of vaccines with chemotherapy in PC
Trial

Country and eligibility

Intervention and objective

sample size

Result

Yamamoto et
al. (2005)68

Japan. PS 0-2, and not
treated for four weeks
before entering to trial

A phase 1 trial of peptide vaccine of
mucin-1 with Incomplete Freund's

N=9 overall, 6 were
PC

Ramanathan
et al. (2005)69

U.S.A, PC patients with
resectable or localized
tumors. No prior
chemotherapy or RT
was permitted.
Performance status 0-2

N=16 patients with
resected or locally
advanced PC

Kimura et al.
(2012)70

Finland. A
retrospective single
hospital-based study

a phase I study with a primary
clinical objective: Evaluate the
toxicity and safety of the MUC1
vaccine with SB-AS adjuvant.
Secondary objective: Evaluate the
disease-free and overall survival of
patients
DC-based immunotherapy (DC
vaccine alone or DC vaccine plus
lymphokine-activated killer [LAK]
cell therapy) in combination with
the standard chemotherapeutic
agents

Seven had progressive
disease and 1 SD. There was
a tendency for increased
circulating anti-MUC1 IgG
antibody after vaccination.
The median OS was 12
months, and 13 patients
died.

Gjersten et al.
(2001)71

Norway. Resectable
and metastatic PC. Life
expectancy > 2 months.
No prior chemo or RT
within four weeks

Phase I/ II study of KRAS peptide
vaccines combined with
Granulocyte-Macrophage ColonyStimulating Factor

Abou-Alfa et
al. (2011)72

South Korea. Age > 18,
resectable PC with K-

A pilot study with a primary
objective of assessing the safety of

N=49 metastatic PC

Two patients a CR, 5 had
partial remission, and 10 had
SD. Median OS was 360 days,
longer than historical control.
OS was longer in DC
vaccine+LAK plus
chemotherapy vs. those who
did not receive LAK (396 days
vs. 229 days)
N=48, in which ten 90% resectable and 32% of
were resectable, 38 the unresectable achieved
were metastatic PC SD. Mean OS was 25.6
months in the resectable vs.
16.7 months in the historical
control.
N=24 patients with recurrence-free survival of
resectable PC
8.6 months (CI: 2.96 –19.2),
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RAS mutation. Single
institute-based study

immunizing patients against their
tumor-specific mutated K-ras

and a median OS of 20.3
months (CI, 11.6–
45.3).However, the median
OS was not different in those
who received adjuvant KRAS
vaccine and in those who did
not

Muscarella et
al. (2012)73

Multi-center phase II

N=39 resectable
PC, (GI-4000 n=19,
Placebo n=20)

Weden et al.
(2011)84

Norway. A
retrospective study of
two previous trials

A randomized, placebo-controlled,
double-blind, adjuvant trial of the
efficacy, immunogenicity, and safety
of GI-4000 plus gem versus gem
alone in patients with resected
pancreas cancer with activating RAS
mutations/survival and immunology
analysis of the R1 subgroup
K-ras vaccination in resectable PC
patients. The objective was to
determine long-term survival in
these patients

Middleton et
al. (2014)75

U.K. Multi-center phase
III trial. Age >18,
performance status 02, localized or
advanced PC

Patients were randomly assigned to
receive either chemotherapy alone,
chemotherapy with sequential
GV1001 (sequential
chemoimmunotherapy), or
chemotherapy with concurrent
GV1001 (concurrent
chemoimmunotherapy)

N=1,062 patients
with localized or
metastatic PC

Median OS was not different
in the three groups. 7.9
months, 6.9 months, and 8.4
months in the chemotherapy
group, sequential
chemoimmunotherapy, and
concurrent
chemoimmunotherapy

Pharmexa
(2008)76

International multicenter phase III trial

Objective: Determine the best way
to use GV1001 in combination with

N=360 with
resectable PC

No survival differences in

N=23 patients with
resected PC

The GI-4000 group had an
11.4-week advantage in
median overall survival (524
Days vs. 444 Days), a 16%
advantage in 1-year survival
(72% vs. 56%), and a 4.6week advantage in median
RFS (287 Days vs. 255 days)
Median OS was 27.5 months
for the entire cohort and a 5year survival rate of 29% and
22% in those who showed an
immune response and those
who did not
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chemotherapy in patients with nonresectable pancreatic cancer. The
primary endpoint of the trial is
survival, and secondary endpoints
include time to progression and
safety.

Buanes et al.
(2008)77

Bernhardt et
al. (2006)78

Jaffe et al.
(2001)79

in the GV1001 plus
gemcitabine vs.
chemotherapy alone

Phase III trial. Patients
with advanced PC,
performance status 0-2

This phase III trial was conducted to
determine the impact on overall
survival of G monotherapy vs.
GV1001 in sequential combination
with G in unresectable and
metastatic PC. The primary endpoint
was OS

N=365 patients
with advanced PC

The study ended prematurely
after 174 deaths occurred.
Median OS was 7.3 / 5.9
months (HR 0.8; 95% CI 0.6–
1.0). Median progressionfree survival (PFS) was 3.7 /
1.9 months (HR 0.5; 95%CI
0.4–0.7)

Norway. Phase I/II
study. Age > 18, with
unresectable PC and
adequate liver, renal,
and heart functions.

Patients were divided into three
groups, given either a low dose
(n=11), an intermediate dose (n=17),
or a high dose of the vaccine (n=20).
Objectives: investigate the safety
and tolerability of GV100

N=48 unresectable
PC

U.S.A. Single hospitalbased phase I trial.
Resectable PC,
performance score 0-1,
age >18, no
metastases, stage 1, 2,
and 3

A phase I trial of allogeneic GM-CSF–
transduced cancer vaccine
composed of these two allogeneic
GM-CSF–secreting pancreatic tumor
lines. Fourteen patients with stage
1, 2, or 3 with resectable PC to
assess the safety and the induction
of systemic antitumor immune
responses

N=14 PC patients
with stage 1, 2, and
3 who received
surgery

The median OS was (8.6 vs.
4.0 vs. 5.1 months) for
intermediate, high, and low
dose. Median survival was
significantly longer in the
immune responders
compared to the
nonresponders (7.2 vs. 2.9
months, P <0.001)
Three patients had a diseasefree survival of 25 months
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Lutz et al.
(2011)80

U.S.A. A single hospitalbased study of
granulocytemacrophage colonystimulating factor
vaccine

Patients received the vaccine at
N=60 resectable
specified intervals integrated with
PC.
adjuvant chemoradiotherapy and
Chemo. Primary and secondary
endpoints: disease-free survival, OS,
toxicity, induction of mesothelinspecific T cell responses
Laheru et al.
U.S.A. An open-label
Two GM-CSF secreting pancreas
N=50 PC with
(2008)85
pilot study. Patients
cancer cell lines (CG8020/CG2505)
metastatic disease
with histological
were administered. Patients
confirmed PC, and
received GM-CSF alone or in
normal liver, renal, and sequence with Cyclophosphamide.
hematological
Primary and secondary objective:
functions.
safety and duration of immunity,
time to disease progression (TTP)
and median OS
CR: complete response GM-CSF: granulocyte-macrophage colony-stimulating factor

The median disease-free
survival was 17.3 months
(95% CI, 14.6–22.8) with a
median OS of 24.8 months
(95% CI, 21.2–31.6)

OS was not improved. higher
rate of Mesothelin-specific T
cell responses was reported
in the cohort who received
chemotherapy prior to
immunotherapy
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Research Gaps
Overall, the majority of these trials indicated that the various types of vaccines used
alone or in combination with chemotherapy were safe and well-tolerated. The data derived
from these vaccine trials are promising as multiple have shown survival better than expected
from historical controls. The reason that improved OS has been reported in the vaccination trials
but not with checkpoint inhibitors may be due to the lack of enough patient numbers, time of
the initiation of the drugs, rationale combinations, and selection of patient cohort in the
checkpoint inhibitors studies. The lack of response of PC to mono immunotherapy in the initial
trials is also partly attributed to the unique immunosuppressive tumor microenvironment of PC,
which consists of a dense fibrotic stroma and a scarcity of T cell infiltration.22,43 Despite the lack
of data indicating the survival benefit of immunotherapy in PC50-53, many patients are prescribed
immunotherapy, and many current clinical trials are looking into the efficacy of immunotherapy
in PC.43,49 As of now, no survival data is available to guide clinicians.
However, there is a strong counter-argument that combining immunotherapy with
other standard treatments has the potential to amplify the efficacy of immunotherapy in PC.
Preclinical and clinical studies have indicated that chemotherapy and radiation therapy induce
immunogenic cell death, increase tumor-specific T cell infiltration, decrease Treg cells and
suppress Myeloid-derived suppressor cells (MDSC), which immunotherapy can utilize to improve
immune response.22,86-88 In preclinical studies of PC, immunotherapy has elicited tumor
regression and improved survival when used in combination with chemotherapy.88-90 Radiation
therapy can also augment the effect of immunotherapy through the abscopal effect. After RT,
injury to the tumor cells causes the release of tumor-associated antigens (TAAs), cellular dangerassociated molecular patterns (DAMPs), and cytokines, thus stimulating a tumor-specific
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immune response and enhancing the traffic of immune cells leading to the elimination of the
tumor cells.91-94
These preclinical studies led to the design of some of the current clinical trials of
immunotherapy combined with chemotherapy and radiation therapy, few of which have
reported encouraging preliminary findings.43,49,60-62,95 A study that enrolled 34 patients with
metastatic PC investigated the combination of anti-CTLA4 with gemcitabine and reported a
median OS of 7.4 months (CI: 5.8–9.4) longer than the historical data for gemcitabine alone.60
Another trial of 16 patients with advanced PC, combined gemcitabine with ant-CTLA4 and
reported a median progression-free survival (PFS) of 2.5 months (CI 0.8-4.8), and a median OS of
8.5 months (CI 2.2-10.3).61
An early-phase trial of anti-PD-1 with 50 patients, investigated the safety of nivolumab
in combination with nab-paclitaxel (nab-P) ± gemcitabine in advanced PC.62 The median PFS was
5.5 months, and the median OS was 9.9 months. A dose-escalation phase 1 trial which included
22 patients with advanced PC used CD40 agonist combined with gemcitabine reported a median
PFS of 5.6 months, and a median OS of 7.4 months (CI: 5.5-12.8 ), longer than the median PFS of
2.3 and median OS of 5.7 months in Gemcitabine alone.62 A study of a human chemokine
receptor 2 (CCR2) in combination with chemotherapy that included 49 patients reported 49%
overall response for CCR2 plus chemotherapy arm with 97% stable disease rate compared to no
overall response and 80% of stable disease rate in the chemotherapy alone arm.95,96
Immunotherapy can also have a pivotal role in the early stage or resectable PC. Up to
date, the utilization of immunotherapy has been in unresectable PC because nothing else has
worked and immunotherapy is used a last attempt of treatment.91,97-100 However, the newer
trials are suggesting that patients with localized disease who have a high risk of
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micrometastases may also benefit from immunotherapy.101-105 More than, 60-90% of PC patients
develop locoregional or distant recurrence after resection due to occult micrometastases.106-109
Early-stage PC patients also have low tumor burden and immunotherapy may be a plausible
treatment option in these patients.101,103
The objective of this research was to use the NCDB database, which captures 70% or
more of newly diagnosed cancer cases nationwide, and performs an analysis with more robust
patient numbers and investigate if immunotherapy is truly clinically beneficial and use that to
help design future clinical trials.
Overall Goal and Specific Aims
The overall goal of this current research is to understand the potential role of
immunotherapy in PC survival and determine how to incorporate immunotherapy into the
current standard-of-care PC treatment paradigms. We hypothesize that immunotherapy will
improve the survival of resectable and unresectable PC and that combining immunotherapy
with other treatments may differentially alter the effect of immunotherapy on patient
outcomes. The next four chapters will be used to answer research questions related to the use
of immunotherapy and its impact on the OS of patients diagnosed with PDAC. The national
cancer database (NCDB) was used for answering the research questions. The NCDB, a joint
program of the Commission on Cancer of the American College of Surgeons and the American
Cancer Society, is one of the largest cancer databases in the world which captures more than
70% of the newly diagnosed cancer cases annually in the United States of America. It is
innovative because the majority of the previous studies had low power and included a small
number of patients.
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This dissertation identifies factors associated with receiving immunotherapy and
investigates the impact of immunotherapy, including the treatment sequence on the OS of
unresectable and resectable PDAC patients. The specific aims, along with their related research
hypotheses and the associated manuscripts are listed below:
Manuscript 1: The impact of immunotherapy on the survival of pancreatic adenocarcinoma
patients who do not receive definitive surgery of the tumor
Specific aim 1a: Identify patient and disease characteristics associated with the use of
immunotherapy in unresectable PDAC
Hypothesis: Certain demographic and tumor-related factors are associated with the use
of immunotherapy
Specific aim 1b: Evaluate the impact of immunotherapy in combination with other standard-ofcare treatments on the survival of unresectable PDAC patients
Hypothesis: Combining immunotherapy with RT, chemotherapy, and chemoradiation
has a superior impact on OS than these treatments without immunotherapy in resectable PC
Manuscript 2: The impact of immunotherapy on the survival of pancreatic adenocarcinoma
patients who received definitive surgery of the pancreatic tumor
Specific Aim 2a: Identify the predictors of receiving immunotherapy in resectable PDAC patients
Hypothesis: Certain demographic and tumor-related factors are associated with the use
of immunotherapy
Specific aim 2b: Examine the impact of immunotherapy with other standard-of-care treatments
on the survival of resectable PDAC
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Hypothesis: Combining immunotherapy with RT, chemotherapy, and chemoradiation
has a superior impact on OS than these treatments without immunotherapy in resectable PC
Manuscript 3: The impact of the sequence of immunotherapy on the survival of pancreatic
adenocarcinoma patients: a retrospective analysis of the national cancer database
Specific Aim 3a: Identify the treatment sequence of immunotherapy with other standard-ofcare treatments on the survival of unresectable PDAC patients
Hypothesis: The OS of patients who start immunotherapy within 30 days of RT or
chemotherapy is superior to those who receive treatments more than 30 days of each other in
unresectable PDAC
Manuscript 4: The impact of neoadjuvant and adjuvant immunotherapy on the survival of
pancreatic cancer patients: a retrospective analysis
Specific Aim 3b: Identify the treatment sequence of immunotherapy with other standard-ofcare treatments on the survival of resectable PDAC patients
Hypothesis: The OS of resectable PDAC patients who receive neoadjuvant
immunotherapy is improved compared to patients who receive adjuvant immunotherapy
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CHAPTER 2
IMMUNOTHERAPY AND THE SURVIVAL OF UNRESECTABLE PANCREATIC CANCER
PATIENTS

Abstract
Background and purpose: Immunotherapy has shown excellent efficacy in many cancers, but its
role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. The objective of this study is
to investigate the impact of immunotherapy on the overall survival of PDAC patients who did
not receive surgery of the pancreas using the National Cancer Database (NCDB). Materials and
methods: Patients with pancreatic adenocarcinoma who did not undergo surgery were
identified from NCDB. Cox proportional hazard models were employed to assess the impact of
immunotherapy on survival after adjusting for age of diagnosis, race, sex, place of living, income,
education, treatment facility type, insurance status, year of diagnosis, and treatment types such
as chemotherapy and radiation therapy. Results: Of 263,886 patients who were analyzed, 911
(0.35%) received immunotherapy. Among patients who received chemotherapy (101,546), and
chemoradiation (30,226) therapy, 555/101,546 (0.55%) received chemotherapy plus
immunotherapy, and 299/3,0226 (0.99%) received chemoradiation plus immunotherapy. In a
multivariable analysis adjusted for the factors mentioned above, immunotherapy was
associated with significantly improved OS (HR: 0.87, CI: 0.80-0.94; P<0.001) compared to no
immunotherapy. Chemotherapy plus immunotherapy was significantly associated with
improved OS (HR: 0.85, CI: 0.77-0.94; P <0.001) compared to chemotherapy without
immunotherapy.Further, chemoradiation plus immunotherapy was associated with significantly
improved OS (HR: 0.80, CI: 0.71-0.94; P <0.001) compared to chemoradiation alone. Conclusion:
In this study, the addition of immunotherapy to chemotherapy and chemoradiation therapy was
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associated with significantly improved OS in PDAC patients without definitive surgery. The study
warrants further future clinical trials of immunotherapy in PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents 3.2% of all cancer cases, but it is
responsible for 7.2% of all cancer deaths in the United States.6 Each year, more than 53,000
people in the U.S. are diagnosed with PDAC, while more than 34,000 people die from it.6 It is
predicted that by 2030, PDAC will become the second leading cause of cancer death.7 Due to the
lack of early detection methods, lack of early signs and symptoms, late presentation, disease
heterogeneity, and treatment resistance, PDAC is challenging to treat.14 More than 80% of the
patients present with locally advanced (non-resectable) or metastatic disease, while only 20%
present with resectable cancer.15 The five-year survival is 8.1% and 22% in non-resectable and
resectable PDAC patients.16,48 Surgery is the only curative treatment of pancreatic cancer (PC)
that improves overall survival (OS) by only ten months.110 Chemotherapy makes up the
backbone of treatment for non-resectable patients, but due to the chemotherapy-resistant
characteristic of PDAC, it only improves OS from 6 to 11 months.21,22,111 In addition to
chemotherapy, most of the non-resectable patients also receive radiation therapy (RT) to
improve local control or prevent future symptoms.112
Due to the minimal effect of the current treatments, novel treatment strategies such as
immunotherapeutics have been proposed and occasionally used in an off label setting in PDAC,
mostly extrapolating the utility in various other malignancies. Many current clinical trials are
looking into the efficacy of immunotherapy in PDAC43,49,113, but no survival data is available to
guide clinicians. Despite the lack of data indicating the survival benefit of immunotherapy in
PDAC50-53, many patients are prescribed immunotherapy. The lack of response of PDAC to mono
immunotherapy in the initial trials is partly attributed to the unique immunosuppressive tumor
microenvironment, which consists of a dense fibrotic stroma and a scarcity of T cell
infiltration.22,113 It is also possible that the negative results were due to the small sample size and
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inclusion of heavily pretreated advanced PDAC patients. There is a strong counterargument that
combining immunotherapy with other standard treatments has the potential to amplify the
efficacy of immunotherapy in PDAC.
Pre-clinical and clinical studies have indicated that chemotherapy and RT induce
immunogenic cell death, increase tumor-specific T cell infiltration, decrease Treg cells and
suppress Myeloid-derived suppressor cells (MDSC), which immunotherapy can utilize to improve
immune response.22,87,88 In pre-clinical studies of PDAC, immunotherapy has elicited tumor
regression and improved survival when used in combination with chemotherapy.89,90,114 Preclinical studies have also found that the combination of RT and targeted Programmed cell death
receptor 1, and programmed cell death receptor ligand 1 therapy activates cytotoxic T-cells,
reduces MDSC, and induces an abscopal response.38,114,115 A pre-clinical study demonstrated that
RT is synergistic with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) antibody and induces
systemic anti-tumor responses in a poorly immunogenic carcinoma compared to anti-CTLA-4
monotherapy.116
The results of these pre-clinical studies in various cancers have led to the design of some
of the current clinical trials of immunotherapy combined with chemotherapy and RT43,49,113. Early
phase trials of combining immunotherapy, especially checkpoint inhibitors with chemotherapy
in pancreatic cancer, have reported some encouraging findings60-62,95,96. These trials have
reported improved median OS for patients who received checkpoint inhibitors with
chemotherapy compared to historical data60-62,95,96.
The objective of this study is to investigate the impact of immunotherapy on the overall
survival of PDAC patients who did not receive definitive surgery of the pancreas using the
National Cancer Database (NCDB). This manuscript only includes patients who did not receive
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definitive because patients who do or do not receive definitive surgery are two different
populations of patients. Patients who receive surgery do significantly better than those who do
not undergo surgery. The median survival is 17-23 months in resectable and 4-6 months in
nonresectable PDAC117,118.

Methods
Data Source
The data were extracted from the National Cancer Database (NCDB), which is a joint
program of the Commission on Cancer of the American College of Surgeons and the American
Cancer Society. It captures 70% or more of newly diagnosed malignancies in the United States
annually. Since all patient information in the NCDB database is de-identified, this study was
exempt from institutional review board evaluation
Study Population
Patients age 18 or older, diagnosed with PDAC between 2004 and 2016, were included
in the study. Patients who received definitive surgery of the tumor, and those who had missing
information on RT, chemotherapy, and immunotherapy were excluded. Patients with unknown
or missing information about other covariates were not included in the adjusted multivariable
analysis. The surgical site-specific code was used to identify patients with definitive surgery of
the tumor and exclude them. There was not enough sample size for immunotherapy plus RT vs.
RT alone, and therefore the analysis for this group was not performed. The ICD-O-3 histology
codes of 8000, 8010, 8020-8022, 8140, 8141, 8211, 8230, 8500, 8521, 8050, 8260, 8441, 8450,
8453, 8470-8473, 8480, 8481, 8503,8250,8440, 8560 were used for defining PDAC.
End Points
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The primary outcome was overall survival (OS) calculated from the date of diagnosis to
the date of death from any cause. Those alive or lost to follow up were censored at the date of
the last contact.
Predictors or explanatory variables
The main predictors of this study were immunotherapy, immunotherapy combined with
chemotherapy, and immunotherapy combined with chemoradiation. Age of diagnosis, gender,
race, urban and rural living status, income, education, treatment facility type, comorbidity score,
insurance status, year of diagnosis, and receipt of chemotherapy, radiation therapy, and
immunotherapy were other explanatory variables included in the study.
Statistical Analyses
Descriptive statistics for categorical and continuous variables were reported.
Multivariable logistic analysis was performed to identify predictors of receiving immunotherapy,
and the odds ratio was reported as the measure of association with the probability of using
immunotherapy. Kaplan-Meier curves and log-rank tests were utilized to report the difference in
median OS between groups. Multivariable analysis of OS was conducted using Cox proportional
hazards regression analysis and estimated hazard ratios with associated 95% confidence
intervals (CI). A P-value of 0.05 was used for a significant level, which was based on two-sided
tests. Separate multivariable Cox proportional hazard regression models were developed for the
hazard ratio of immunotherapy combined with chemotherapy and chemoradiation as these
combinations are mutually explosive variables. The SAS 9.4 software was used for the analysis.
To assess the quality and robustness of the final model and prevent overfitting of the
logistic and Cox regression models, the final model was validated by splitting the data to testing
and validation sets using the bootstrap sampling method. Bootstrap sampling is a statistical
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technique for random sampling with replacement and is determined to be an excellent method
for model performance. We performed 1,000 bootstrapping samples and compared the
concordance index (C-Index) of the bootstrap model with the C-Index of the original model. The
C-Index of the original model for multivariable logistic regression analysis was 0.81, and the CIndex after 1,000 bootstraps was 0.81. The C-Index bias for the logistic model was 0.00. The CIndex for the original survival model of immunotherapy was 0.685, and for the survival model
after 1,000 bootstraps was 0.685. The C-Index bias for the survival model was 0.00. The details
of the original and bootstrap models, including the hazard ratio and C-Index, are provided in
supplemental tables 1-5. SAS 9.4 and R 6.2 were used for analysis and bootstrap sampling.

Results
In total, 263,886 patients diagnosed with PDAC between 2004 and 2016 who did not
receive definitive surgery met the inclusion criteria and were included for the analysis. Of the
263,886 patients, 911 (0.35%) received immunotherapy. Among patients who received
chemotherapy (101,546), RT (5,111), and chemoradiation (30,226) therapy, 555/101,546
(0.55%) received chemotherapy plus immunotherapy, 9/5,111 (0.18%) received RT plus
immunotherapy, and 299/30,226 (0.99%) received chemoradiation plus immunotherapy. The
median age was 71.00, with a range of (18.0-90.0) years. The majority of patients were White,
insured, living in the urban areas, had Charlson/Deyo Score of zero, had a high school degree,
had income >=$35,000, and received chemotherapy. In the multivariable logistic analysis, older
age, black race, no insurance, Charlson/Deyo Score of 1 and 2, community hospital, being less
educated, diagnosed before 2011, not receiving chemotherapy, and not receiving RT were all
less likely to receive immunotherapy compared to their counterparts (Table 4).
Based on results from the Kaplan Meier curves, patients who received immunotherapy
had significantly improved median overall survival compared to patients who did not receive
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immunotherapy (Figure 1a) with an absolute median OS benefit of 6.33 [10.60 vs. 4.27; p
<0.0001] months. Subset analysis revealed that patients who received chemotherapy plus
immunotherapy had significantly improved median OS compared to those who receive
chemotherapy alone (Figure 1b) with an absolute median OS benefit of 2.33 [9.30 VS. 6.97; p
<0.0001] months. Similarly, patients who received chemoradiation plus immunotherapy had
significantly improved median OS compared to patients who received only chemoradiation
(Figure 1c) with an absolute median OS benefit of 3.38 [14.42 vs. 11.04; p <0.0001] months.
In univariate Cox Proportional analysis (Table 5), immunotherapy was associated with
significantly improved OS with a hazard ratio (HR) of 0.59 (CI: 0.55-0.64.1; P <0.0001).
Significantly improved OS was also noticed in Immunotherapy plus chemotherapy vs.
chemotherapy alone (HR: 0.82, CI: 0.75-0.90; P <0.0001), and immunotherapy plus
chemoradiation vs. chemoradiation alone (HR: 0.74, CI: 0.65-0.83; P <0.0001). In the univariate
Cox analysis, older age, low education, low income, treatment at a community hospital,
Charlson/Deyo Score of 1 and 2, diagnosis before 2011, not receiving RT, and not receiving
chemotherapy were all associated with significantly decreased OS, while Black race and nonwhite non-black race were associated with significantly improved OS.
In the multivariable Cox proportional hazard analysis (Table 5), receipt of
immunotherapy, female sex, and the non-white non-black race was associated with significantly
improved OS, while older age, low income, treatment at a community hospital, Charlson/Deyo
of one and two, diagnosis before 2011, not receiving chemotherapy, and not receiving RT were
associated with significantly decreased OS. In the multivariable analysis adjusted for all the
above factors, immunotherapy was associated with significantly improved OS (HR: 0.88, CI: 0.810.95; P<0.0001) compared to no immunotherapy. The results stayed the same when patients
with no treatments were excluded from the analysis. Treatment with chemotherapy plus
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immunotherapy was significantly associated with improved OS (HR: 0.86, CI: 0.78-0.98; P
<0.001) compared to chemotherapy without immunotherapy. Further, chemoradiation plus
immunotherapy was associated with significantly improved OS (HR: 0.80, CI: 0.70-0.92; P
<0.004) compared to chemoradiation alone. Both models were adjusted for the same factors
mentioned previously. The one- and two-year survival rate was 60% (CI: 54%-66%) and 23% (CI:
18%-28%) for chemoradiation plus immunotherapy, 37% (CI: 33%-42%) and 11% (CI: 8%-13%)
for chemotherapy plus immunotherapy, 45% (CI: 45%-46%) and 14% (CI: 13%-14%) for
chemoradiation alone, and 28% (CI: 27%-28%) and 9% (CI: 8%-9%) for chemotherapy alone.
Table 6 has the results of the univariate and multivariable analysis.
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Table 4. Multivariable logistic analysis of the factors associated with the receipt of immunotherapy in PDAC patients with no surgery
Variable

Immunotherapy

No Immunotherapy

Total

911 (0.35%)

262,975 (99.65%)

263,886

Age at diagnosis, Median (range)

64.00 (21-90)

71.00 (18-90)

Sex

Male

497 (54.56)

Female

Race

Education

Income

Place of Living

Odds Ratio

95% CI

P

263,886

0.97

0.97-0.98

0.0001

131,965 (51.18)

132,462 (50.20)

1

Reference

414 (45.44)

131,010 (49.82)

131,424 (49.80)

White

784 (87.21)

217,747 (83.77)

218,531 (83.78)

1

Reference

Black

75 (8.34)

33,124 (12.74)

33,199 (12.73)

0.66

0.52-0.85

0.002

Other

40 (4.45)

9,067 (3.49)

9,107 (3.49)

1.08

0.76-1.54

0.68

Unknown

12

3,037

3,049

>=13% HG

317 (35.11)

114,060 (43.55)

114377 (43.52)

0.77

0.66-0.90

0.001

<13%

586 (64.89)

147,832 (56.45)

148,418 (56.48)

1

Reference

Unknown

8

1,083

1,091

>=$35,000

593 (65.74)

152,161 (58.13)

152,754 (58.16)

1

Reference

<35,000

309 (34.26)

109,590 (41.87)

109,899 (41.84)

Unknown

9

1,224

1,233

Urban

862 (97.95)

251,360 (98.11)

252,222 (98.11)

Rural

18 (2.05)

4,843 (1.89)

4,861 (1.89)

Unknown

31

5,768

6,803

Academic

589 (65.59)

100,414 (38.43)

101,003 (38.52)

NS

NS

1

0.52

Reference
NS

1

0.331

Reference

0.49
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Hospital Type

Community

309 (34.41)

160,897 (61.57)

161,206 (61.48)

Unknown

13

1,664

1,677

Insured

847 (98.26)

249,219 (96.94)

Not insured

15 (1.74)

Unknown
Charlson/Deyo
Score

Insurance Status

M stage

Chemotherapy

Radiation Therapy

Year of Diagnosis

0.38

0.33-0.45

250,066 (96.95)

1

Reference

7,856 (3.06)

7,871 (3.05)

0.44

0.27-0.78

49

59,00

5,949

0

716 (78.59)

171,219 (65.11)

171,935 (65.16)

1

Reference

1

154 (16.90)

63.980 (24.33)

64,134 (24.30

0.78

0.65-0.93

0.007

>=2

41 (4.50)

27,776 (10.56)

27,817 (10.54)

0.61

0.44-0.84

0.003

M0

449 (51.14)

116,598 (45.95)

117047 (45.97)

1

Reference

M1

429 (48.86)

137,142 (54.05)

137,571 (54.03)

Yes

854 (93.74)

130,918 (49.78)

131,772 (49.94)

1

Reference

No

57 (6.26)

132057(50.22)

132,114 (50.06)

0.12

0.08-0.14

Yes

308 (33.81)

35,029 (13.32)

35,337 (13.39)

1

Reference

No

603 (66.19)

227,946 (86.68)

228,549 (86.61)

0.61

0.52-0.71

0.0001

2004-2010

451(49.51)

126180 (47.98)

126,631 (47.99)

NS

0.65

2011-2016

460 (50.49)

136,795 (52.02)

137,255 (52.01)

NS

1

Reference

0.0001

0.010

0.79

0.0001
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Figure 1a: Overall survival of unresectable PDAC patients with (red) or without (blue)
immunotherapy

Figure 1b: Overall survival of unresectable PDAC patients who received chemotherapy with
(Red) or without (blue) immunotherapy
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Figure 1c: Overall survival of unresectable PDAC patients who received chemoradiation with
(red) or without (blue) immunotherapy
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Table 5. Univariable and multivariable Cox analysis and the OS of PC patients who did not receive definitive surgery
Variable

Univariable analysis

Multivariable analysis

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

Age at diagnosis (continuous)

1.02 (1.02-1.02)

<0.0001

1.01 (1.01-1.01)

<0.0001

Sex

Male

Reference

Female

0.99 (0.99-1.00)

White

Reference

Black

0.97 (0.96-0.98)

<0.0001

0.99 (0.98-1.01)

<0.21

non-white non-black

0.87 (0.85-0.89)

<0.0001

0.89 (0.86-0.91)

<0.0001

>=13% HG

1.05 (1.04-1.06)

<0.0001

0.99 (0.98-0.99)

0.021

<13% HG

Reference

Reference

>=$35,000

Reference

Reference

<$35,000

1.09 (1.08-1.100)

Urban

Reference

Rural

1.08 (1.05-1.11)

Academic

Reference

Community

1.28 (1.27-1.29)

Insured

Reference

Not insured

0.98 (0.95-1.00)

0

Reference

Race

Education

Income

Place of Living

Hospital Type

Insurance Status

Reference
<0.18

0.94 (0.94-0.95)

<0.0001

Reference

<0.0001

1.07 (1.06-1.08)

<0.0001

Reference
<0.0001

1.05 (1.01-1.08)

0.008

Reference
<0.0001

1.18 (1.17-1.19)

<0.0001

Reference
0.066

1.07 (1.04-1.09)
Reference

<0.0001
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Charlson/Deyo
Score

1

1.17 (1.16-1.18)

<0.0001

1.11 (1.11-1.13)

<0.0001

>=2

1.52 (1.50-1.54)

<0.0001

1.35 (1.33-1.37)

<0.0001

2004-2010

1.18 (1.17-1.19)

0.0001

1.18 (1.17-1.19)

0.0001

Year of Diagnosis

2011-2016

Reference

M stage

M0

0.66 (0.65-0.66)

M1

Reference

Yes

Reference

No

2.15 (2.13-2.17)

Yes

Reference

No

1.76 (1.73-1.78)

Yes

0.59 (0.55-0.64)

No

reference

Chemotherapy

Radiation Therapy

Immunotherapy

Reference
0.0001

0.56 (0.56-0.57)

0.0001

Reference
<0.0001

2.10 (2.08-2.12)

<0.0001

Reference
<0.0001

1.11 (1.09-1.12)

<0.0001

0.87 (0.80-0.94)
<0.0001

reference

<0.0004
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Table 6. Univariate and multivariate analysis of Combining Immunotherapy with Chemotherapy and Radiation therapy
Variable

N (%)

Univariable analysis
Hazard Ratio (95% CI)

Chemo and immunotherapy
combination

Chemotherapy Only

100,991 (99.45%)

Reference

555 (0.55%)

0.82 (0.75-0.90)

Chemoradiation Only

29,927 (99.01%)

Reference

Chemoradiation plus

299 (0.99%)

0.74 (0.65-0.83)

Chemo plus

Multivariable analysis
P

Hazard Ratio (95% CI)

P

Reference
<0.0001

0.85 (0.77-0.94)

0.001

Immunotherapy
Chemoradiation plus
immunotherapy combination

Reference
<0.0001

0.81 (0.71-0.94)

Immunotherapy
Two different models were developed for the multivariable analysis of table 3 because the treatment combination variables were
mutually exclusive.

0.004
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Discussion
The current study compared the survival outcomes of PDAC patients without surgery
who received chemotherapy with and without immunotherapy and those who received
chemoradiation with and without immunotherapy. Our analysis demonstrated that adding
immunotherapy to either chemotherapy or chemoradiation therapy led to a significant OS
benefit in both univariate and multivariable Cox regression analysis. What is unique about our
study is that chemoradiation plus immunotherapy was associated with a significantly improved
OS, which to our knowledge, has not been investigated yet.
The resistance of PDAC to the standard-of-care treatments is multifactorial24. Local
therapies such as surgery and RT failed to show significant success because PDAC metastasizes
microscopically early in the disease course, which limits the effectiveness of these treatments
109,119

. The presence of a strong desmoplastic stroma and the ability of the PDAC cells to go

through a profound oncogenic alteration contributes to the failure of systemic therapies in
PDAC24,120,121. The tumor microenvironment (TME) of PDAC evades immune response by upregulating programmed-death ligand 1, downregulating CTLA4, recruitment of MDSC, and
tumor-associated macrophages122-127. Based on these characteristics of the tumor, a
multidisciplinary treatment approach of combining various systemic therapies such as
immunotherapy and chemotherapy with each other or with local therapies such as RT may
deliver better results. Immunotherapy may produce synergetic interaction with chemotherapy
and radiation therapy as they increase tumor-specific T cell infiltration, decrease Treg cells, and
suppress MDSC86,88,128,129. Various combination treatment strategies have been proposed to
overcome the resistance of PDAC to immunotherapy. The combination of immunotherapies
with chemotherapy and chemoradiation in PDAC represents a promising strategy to stimulate
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immunogenicity, improve antigen recognition, increase the presentation of neoantigen, utilize
abscopal effect, inhibit tumor-mediated immunosuppression, and improve survival130-132.
The OS of patients who only received immunotherapy was not significantly different
from the OS of patients who only received chemotherapy or chemoradiation, indicating that
using immunotherapy alone in PDAC is not more effective compared to other treatments alone
(data not shown). The results of the study remained the same when the analysis was restricted
to patients who received immunotherapy within six months of chemotherapy or
chemoradiation. There was no difference in the OS of patients who received immunotherapy
concurrently with chemotherapy or chemoradiation compared to patients who received
immunotherapy before chemotherapy or chemoradiation, and patients who received
immunotherapy after chemoradiation. No difference may be due to the small sample size of the
non-concurrent groups (the data is not shown). The sequence was investigated separately for
immunotherapy plus chemotherapy and immunotherapy plus chemoradiation.
The improved OS with the addition of immunotherapy to standard treatments reported
in our study may be synergistic. Chemotherapy can recruit and activate dendritic cells, trigger
the release of tumor-specific antigens, and reduce Treg cells130. Chemotherapy, especially
gemcitabine, has been associated with an increase in tumor-specific T cell infiltration, a
decrease in Treg cells, and the suppression of MDSC in pre-clinical and clinical studies 86,129,133.
Chemotherapy causes immunogenic death, which promotes antigen presentation and leads to
the priming of the tumor-specific T cells86,129. Radiation therapy promotes the translocation of
calreticulin, which will enable T cells to clear tumor cells133. More importantly, through the
abscopal effect, RT causes the release of tumor-associated antigens134, which stimulates a
tumor-specific immune response, allowing the immune cells (T-cells) to recognize and attack
both the primary tumor and metastatic disease in a sort of auto-vaccination92,103,135-138. The
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irradiated tumor cells may also release cellular danger-associated molecular patterns and
cytokines that enhance the traffic of immune cells leading to the elimination of the tumor
cells92,136. Chemotherapy and RT also cause the release of neoantigens and upregulation of
inflammatory cytokines, which promote the presentation of the neoantigens in the TME and
thereby increase the immunogenicity of the tumor cells, making them better targets for
immunotherapy94,137-141.
Our results are consistent with the preliminary findings of the ongoing phase 1 trials of
immunotherapy and chemotherapy60-62,95,96. The median OS reported in these trials is similar to
the median OS reported in our study. In phase I trial of 34 patients with metastatic PC, patients
who received anti-CTLA4 with gemcitabine had a median OS of 7.4 months, much longer than
the historical data from chemotherapy alone60. Another trial which included 16 patients with
advanced PC and investigated the combination of gemcitabine with anti-CTLA4 reported a
median OS of 8.4 months61. An early-phase trial with 50 patients investigated anti-PD-1,
nivolumab in conjunction with nab-paclitaxel (nab-P) ± gemcitabine in advanced PDAC, reported
a median OS of 9.9 months with a 6-months OS rate of 73%62. A dose-escalation phase 1 trial of
CD40 agonist combined with gemcitabine of advanced PDAC which include 22 patients reported
a median OS of 7.4 months for patients who received CD40 with gemcitabine compared to 5.7
months for gemcitabine alone95. A study of PF-04136309, a human chemokine receptor 2 (CCR2)
in combination with chemotherapy in patients with borderline resectable or advanced PDAC
that included 49 patients reported 49% overall response rate and 97% stable disease in the
combined arm, while in the chemotherapy alone arm, there was no overall response reported,
but 80% achieved stable disease96.
In this study, chemotherapy plus immunotherapy was associated with significantly
improved OS with a hazard ratio of ((HR: 0.857, CI: 0.776-0.984; P <0.001) compared to
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chemotherapy without immunotherapy. chemoradiation plus immunotherapy was associated
with significantly improved OS (HR: 0.804, CI: 0.702-0.921; P <0.001) compared to
chemoradiation without immunotherapy
To our knowledge, the current study is the first to use an extensive database such as
NCDB and investigate the impact of immunotherapy on the OS of PAD patients who did not get
definitive surgery. The findings of our study, together with early results of some clinical trials,
warrant future large phase III clinical trials of immunotherapy combined with chemotherapy or
chemoradiation in PAD patients.
The strength of the current study is the large sample size. A large sample size allowed us
to adjust for the important patient and tumor characteristics in the multivariable analysis. More
importantly, we were able to stratify patients by definitive surgery. However, our research is not
without limitations, and those limitations are inherent to NCDB which include incomplete data
and ascertainment bias, lack of data about the cause of death, lack of detailed information on
the use of multi-agent chemotherapy regimens, and lack of information on the type of
immunotherapy and if a single or combined immunotherapy was used. Also, the NCDB does not
provide data on the microsatellite-instability status for PDAC patients who are more likely to
respond to immunotherapy. Due to the small sample size, the analysis of comparing the impact
of RT plus immunotherapy vs. RT alone was not performed.
Nevertheless, NCDB provided sufficient patient numbers to assess the impact of
immunotherapy on the OS of PDAC patients, which is difficult to quantify from small early-phase
clinical trials, most of which are single arm. To our knowledge, this study is the most extensive
retrospective study of the use of immunotherapy and its impact on the OS of unresectable PDAC
patients. This research included the majority of patients treated in the United States and is the
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best available resource outside multicenter, randomized trials to investigate the impact of novel
treatments such as immunotherapy on the OS of unresectable PDAC patients.

Conclusion
To our knowledge, the current study is the first study with a robust investigation of the
impact of immunotherapy in combination with chemotherapy and chemoradiation on the OS of
PDAC patients using the NCDB. This research study found significantly improved OS in patients
receiving standard therapies such as chemotherapy and chemoradiation when combined with
immunotherapy. These findings warrant further clinical trials looking into the impact of
immunotherapy combined with chemotherapy and chemoradiation in PDAC patients.
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CHAPTER 3
IMMUNOTHERAPY AND THE SURVIVAL OF RESECTABLE PANCREATIC CANCER
PATIENTS

Abstract
Purpose: Immunotherapy has paved the way for new therapeutic opportunities in cancer but
has failed to show any efficacy in Pancreatic Adenocarcinoma (PDAC), and its therapeutic role
remains unclear. The objective of this study is to examine the impact of immunotherapy in
combination with chemotherapy, RT, and chemoradiation on the overall survival (OS) of PDAC
patients who received definitive surgery of the tumor using the National Cancer Database
(NCDB). Methods and Materials: Patients with PDAC who received definitive surgery of cancer
and were diagnosed between 2004 and 2016 from the NCDB were identified. Cox proportional
hazard analysis was used to assess the survival difference between patients who received
chemotherapy plus immunotherapy and chemoradiation therapy plus immunotherapy and their
counterparts who only receive these treatments without immunotherapy. The multivariable
analysis was adjusted for age of diagnosis, race, sex, place of living, income, education,
treatment facility type, insurance status, year of diagnosis, and treatment types such as
chemotherapy and radiation therapy. Results: In total, 63,154 PDAC patients who received
definitive surgery of the tumor were included in the analysis. Among the 63,154 patients, 636
(1.01%) received immunotherapy. Among patients who received chemotherapy (21,355), and
chemoradiation (21,875), 157/21,355 (0.74%) received chemotherapy plus immunotherapy, and
451/21,875 (2.06%) received chemoradiation plus immunotherapy. In the multivariable analysis,
patients who received immunotherapy had significantly improved OS compared to patients who
did not receive immunotherapy (HR: 0.90; CI: 0.81-0.99; P <0.039). Patients who received
chemoradiation plus immunotherapy had significantly improved OS compared to their
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counterparts who only received chemoradiation without immunotherapy (HR: 0.85 CI: 0.750.95; P <0.008). Conclusions: In this study, the addition of immunotherapy to chemoradiation
therapy but not chemotherapy alone was associated with significantly improved OS in PDAC
patients who received definitive surgery. The study warrants further future clinical trials of
immunotherapy in PDAC.
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Introduction
Pancreatic adenocarcinoma (PDAC) is the 7th leading cause of global cancer deaths and
the third leading cause of cancer deaths in the United States4. In 2019, there were an estimated
56,000 new cases of PDAC and 450,00 deaths142. It is predicted that PDAC will become the
second leading cause of cancer deaths by 2030, after lung cancer7. There are no early detection
tests, and most patients with localized disease have no recognizable symptoms or signs.
Therefore, most PDAC patients are diagnosed after their cancer has metastasized to other
organs143. The five-year survival rate for all stages remains at 5% and has not changed in the last
30 years142.
Surgery is the only curative treatment, but unfortunately, only 15-20 % of patients
present with cancer that is amenable to resection144. Despite significant improvement in surgical
techniques, the five-year survival rate after resection remains at 10-20% with a median survival
of 24 months144,145. A Locoregional and distant recurrence rate of up to 80% after surgery is
reported, which is likely secondary to the presence of occult micrometastatic disease at the time
of resection146,147. The majority of locoregional or distant recurrence occurs within two years
after resection146,147. A rapid autopsy series of patients with known PDAC found that only 30 %
of the patients died with a locally destructive disease with no evidence of distant metastasis. In
comparison, 70 % died with widespread metastatic disease148. The potential of PDAC for early
metastases have convinced scientists to hypothesize that PDAC is a systemic disease at the time
of diagnosis, even when there is no radiographic evidence of distant metastases145.
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Chemotherapy and/or chemoradiation have been combined with surgery to improve
disease control and survival. Unfortunately, the outcomes of combined treatment are still not
very promising. Therefore, there is a desperate need for more effective systemic therapy that
could be combined with the current standard treatment to improve the overall survival (OS) of
the resectable PDAC patients. Strategies of combining novel treatments such as immunotherapy
with surgery have been proposed and could provide a potential successful curative option for
PDAC patients. After making first inroads in cancer in the setting of metastatic melanoma in
2011, immunotherapy has now been approved for advanced melanoma, non-small cell lung
cancer (NSCLC), Hodgkin's lymphoma, head and neck cancer, microsatellite instability-high
cancer, gastric cancer, advanced renal cell cancer, bladder cancer, liver cancer, and Merkel cell
carcinoma42,149.
Immunotherapy is not approved for PDAC but has been occasionally used in an off-thelabel clinical setting for metastatic PDAC extrapolating the utility in various other malignancies.
Despite the inconclusive results of the initial trials of mono immunotherapy in metastatic PDAC,
to date, the utilization of immunotherapy has been primarily in the metastatic setting as a lastditch effort following the failure of currently FDA approved therapies50,150-152. However, new
evidence indicates that immunotherapy could be effective and useful in patients with localized
disease who have a high risk of micrometastases a critical hallmark of PDAC103-105. Occult
metastases and the fact that early-stage cancer presents with the more intact immune system
and lower tumor burden underline the rationale for the use of immunotherapy in resectable
PDAC102,103.
Immunotherapy may be useful in PDAC patients who receive definitive surgery if it is
combined with other treatments such as chemotherapy and radiation therapy (RT). Preclinical
and clinical evidence demonstrates that immunotherapy can have synergistic interaction with
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chemotherapy and RT as they increase tumor-specific T cell infiltration, decrease Treg cells, and
suppress Myeloid-derived suppressor cells (MDSCs)87,88. In preclinical studies of PDAC,
immunotherapy has elicited tumor regression and improved survival when used in combination
with other treatments of cancer, especially chemotherapy89,90. The objective of the current
study is to investigate the impact of immunotherapy combined with chemotherapy and
chemoradiation on the overall survival of PDAC patients who received definitive surgery of PDAC
using the National Cancer Database (NCDB).

Methods
Data Source
The data for this study was extracted from the National Cancer Database (NCDB), which
is a joint program of the Commission on Cancer of the American College of Surgeons and the
American Cancer Society. It captures 70% or more of newly diagnosed malignancies in the
United States annually. This study was exempt from the Institutional Review Board (IRB)
because the de-identified file of the NCDB data was used.
Study Population
The study included patients age 18 or older who were diagnosed with PADC between
2004 and 2016 and received definitive surgery of the tumor. Only patients who were diagnosed
with PDAC were included using the ICD-O-3 histology codes of 8000, 8010, 8020-8022, 8140,
8141, 8211, 8230, 8500, 8521, 8050, 8260, 8441, 8450, 8453, 8470-8473, 8480, 8481,
8503,8250,8440, 8560. The surgical site-specific code was used to identify patients with
definitive surgery of the tumor. Patients who were missing information about RT,
chemotherapy, and immunotherapy were excluded. We also excluded patients with the M1
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stage and those with unknown or missing information about other covariates in the adjusted
multivariable analysis.
End Points
The primary outcome of the current study was the OS of the patients, which was
calculated from the date of diagnosis to the date of death. Patients who were alive or lost to
follow up were censored.
Explanatory variables
The main predictors of OS in this study were immunotherapy, immunotherapy
combined with chemotherapy, and immunotherapy combined with chemoradiation. The age of
diagnosis, gender, race, urban and rural living status, income, education, treatment facility type,
comorbidity score, insurance status, year of diagnosis, and receipt of chemotherapy, RT, and
immunotherapy were other explanatory variables used in the analysis.
Statistical Analyses
Descriptive statistics were reported for categorical and continuous variables.
Multivariable logistic analysis was used to identify the predictors of receiving immunotherapy
and reported the odds ratio as a measure of association with the probability of receiving
immunotherapy. The p-value of 0.10 was used as a cut-off point for a variable to stay in the final
model. OS rates were determined using the Kaplan–Meier method and were compared between
groups using log-rank statistics. Survival time was measured in months from the date of
diagnosis to the date of death. Cox proportional hazards model was used to determine the
significant predictors of OS and estimate the hazard ratio of death as well as its 95% confidence
interval (CI). The potential variables to be adjusted in the multivariable Cox models were the age
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of diagnosis, gender, race, urban and rural living status, income, education, treatment facility
type, comorbidity score, insurance status, year of diagnosis, and receipt of chemotherapy and
RT. Variables with a p-value of 0.2 in the univariate analysis were selected for the multivariable
analysis. A p-value of 0.10 was used as a cut-off point for a variable to stay in the final model.
The p-value of 0.05 was considered significant. Separate multivariable Cox proportional hazard
regression models were developed for the hazard ratio of immunotherapy combined with
chemotherapy and chemoradiation as these combinations are mutually explosive variables. The
C-Index of the original model for multivariable logistic regression analysis was 0.80, and after
1,000 bootstraps was 0.80 with C-index bais of 0.00. The C-Index for the original survival model
of immunotherapy was 0.59, and the survival model after 1,000 bootstraps was 0.59, with a CIndex bias of 0.00. The details of the original and bootstrap models, including the hazard ratio
and C-Index, are provided in supplemental tables 6-10. SAS 9.4 and R 6.2 were used for analysis
and bootstrap sampling.

Results
In total, 63,154 patients diagnosed with PDAC between 2004 and 2016 who received
definitive surgery of the tumor were included in the analysis. Among the 63,154 patients, 636
(1.01%) received immunotherapy. Among patients who received chemotherapy (21,355), and
chemoradiation (21,875), 157/21,355 (0.74%) received chemotherapy plus immunotherapy, and
451/21,875 (2.06%) received chemoradiation plus immunotherapy. The majority of the patients
were White, from urban areas, with high school degrees, Charlson/Deyo Score of zero, the
income of >=$3,5000, received chemotherapy, and treated in academic hospitals. In the
multivariable logistic analysis, older age, female sex, Black race, Charlson/Deyo Score of 1 and 2,
treatment at a community hospital, being less educated, diagnosed before 2011, not receiving
chemotherapy, and not receiving RT were significantly less likely to receive immunotherapy.
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Insurance status, income level, place of living, and non-white non-black race were not
significantly associated with the receipt of immunotherapy. The odds ratio of these factors is
provided in Table 7.
PDAC patients who received immunotherapy had significantly improved median overall
survival OS with an absolute median OS benefit of 7.1 [28.45 vs. 21.36; p <0.0001] (Figure 2a)
months compared to their counterparts without immunotherapy. Patients who received
chemoradiation plus immunotherapy had significantly improved median OS compared to
patients who only received chemoradiation with an absolute median OS benefit of 5.7 [29.31 vs.
23.66; p <0.0001] months (Figure 2c). There was no significant difference in the median OS of
patients who received chemotherapy plus immunotherapy and those who only received
chemotherapy [26.28 vs. 22.70; p <0.051] months (Figure 2b).

55
Table 7. Multivariable logistic analysis of the predictor of immunotherapy in patients who received definitive surgery of the pancreatic
tumor
Variable

Immunotherapy

No Immunotherapy

Total

Age at diagnosis, Median (range)

636 (1.01%)
62.00 (29-90)

62,518 (98.99%)
67.00 (18-90)

63,154
63,154

Male

352 (55.35)

31,719 (50.74)

Female

284 (44.65)

White

Sex

Race

Education

Income

Place of Living

Hospital Type

Odds
Ratio

95% CI

P

0.97

0.97-0.98

<0.0001

32,071 (50.78)

1

Reference

30,799 (49.26)

31,083 (49.22)

0.84

0.72-0.99

574 (92.13)

53,761 (86.84)

54,335 (86.89)

1

Reference

Black

28 (4.49)

5982 (9.66)

6,010 (9.61)

0.48

0.32-0.71

0.0003

Other

21 (3.37)

21,68 (3.50)

2,189 (3.50)

0.79

0.48-1.28

0.338

Unknown

13

607

620

>=13% HG

167 (26.47)

24,941 (40.05)

25,108 (39.91)

0.65

0.54-0.78

0.0001

<13%

464 (73.53)

37,336 (59.95)

37,800 (60.09)

1

Reference

Unknown

5

241

246

>=$35,000

459 (72.74)

38,308 (61.54)

38,767 (61.65)

1

Reference

<35,000

172 (27.26)

23,944 (38.46)

24,116 (38.35)

Unknown

5

266

271

Urban

604 (99.02)

59,667 (98.11)

60,271 (98.12)

1

Reference

Rural

6 (0.98)

1,150 (1.89)

1,156 (1.88)

0.41

0.15-1.11

Unknown

26

1701

1,727

Academic

505 (80.41)

34,074 (55.04)

34,579 (55.30)

1

Reference

Community

123 (19.59)

27831 (44.96)

27,954 (44.70)

0.261

0.21-0.32

NS

0.046

0.160

0.081

0.0001
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Insurance Status

Charlson/Deyo
Score

Chemotherapy

Radiation Therapy

Year of Diagnosis

Unknown

8

613

621

Insured

623 (98.89)

60,145 (97.73)

60,768 (97.74)

1

Reference

Not insured

7 (1.11)

1,399 (2.27)

1,406 (2.26)

0.50

0.24-1.07

Unknown

6

974

980

0

486 (76.42)

40,852 (65.34)

41,338 (65.46)

1

Reference

1

125 (19.65)

16,270 (26.02)

16,395 (25.96)

0.73

0.59-0.90

0.003

>=2

25 (3.93)

5,396 (8.63)

5,421 (8.58)

0.52

0.34-0.79

0.002

Yes

608 (95.60)

42,622 (68.18)

43,230 (68.65)

1

Reference

No

28 (4.40)

19896 (31.82)

19,924 (31.55)

0.21

0.14-0.32

Yes

459 (72.17)

22,068 (35.30)

22,527 (35.67)

1

Reference

No

177 (27.83)

40,450 (64.70)

40,627 (64.33)

0.35

0.29-0.43

<0.0001

2004-2010

330 (51.89)

27,978 (44.75)

28,308 (44.82)

1.27

1.07-1.50

<0.005

2011-2016

306 (48.11.)

34,540 (55.25)

34,846 (55.18)

1

Reference

0.074

0.0001

When we excluded insurance status and place of living the results were the same; therefore, we included them in the multivariable
analysis
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In the univariate Cox Proportional analysis (Table 8), patients who received
immunotherapy had significantly improved OS compared to their counterparts without
immunotherapy (HR: 0.77, CI: 0.70-0.85; P <0.0001). Patients receiving chemoradiation plus
immunotherapy had significantly improved OS compared to chemoradiation alone (HR: 0.80, CI:
0.71-0.89; P <0.008). In the univariate Cox Proportional analysis, patients who received
chemotherapy plus immunotherapy did not notice significantly improved OS compared to their
counterparts (HR: 0.81, CI: 0.66-1.00; P <0.064). Female sex and non-white non-black race were
associated with significantly improved OS, while older age, living in the rural area, treatment at
a community hospital, low income, low education, not receiving chemotherapy or RT, and
diagnosis before 2011 were all associated with significantly decreased OS.
In the multivariable Cox Proportional analysis, immunotherapy, female gender, and nonwhite non-black race were associated with significantly improved OS, while older age, Black
race, treatment at a community hospital, low income, low education, not receiving
chemotherapy or RT, not having insurance, Charlson/Deyo of one and two, and diagnosis before
2011 were associated with significantly decreased OS (Table 8). The multivariable analysis was
adjusted for age of diagnosis, race, sex, place of living, income, education, hospital type,
insurance status, year of diagnosis, and Charlson/Deyo score. Patients who received
immunotherapy had significantly improved OS compared to patients who did not receive
immunotherapy (HR: 0.90; CI: 0.81-0.99; P <0.039). Patients who received chemoradiation plus
immunotherapy had significantly improved OS compared to their counterparts who only
received chemoradiation without immunotherapy (HR: 0.85 CI: 0.75-0.95; P <0.008) (Table 9).
The 1-year and 2-year survival rates were 88% and 60% for chemoradiation plus immunotherapy
patients compared to 81% and 49% in patients who only received chemoradiation (data not
shown). Chemotherapy plus immunotherapy was not associated with significantly improved OS.
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Figure 2a: Overall survival of resectable PDAC patients with (red) or without (blue)
immunotherapy

Figure 2b: Overall survival of resectable PDAC patients who received chemotherapy with (red) or
without (blue) immunotherapy
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Figure 2c: Overall survival of unresectable PDAC patients who received chemoradiation with
(red) or without (blue) immunotherapy
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Table 8. Univariable and multivariable Cox analysis of PDAC patients who received definitive surgery of the pancreatic tumor
Variable

Univariable analysis

Age at diagnosis (continuous)
Sex

Race

Education

Income

Place of Living

Hospital Type

Insurance Status

Multivariable analysis

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

1.01 (1.01-1.02)

<0.0001

1.01 (1.01-1.01)

<0.0001

Male

Reference

Reference

Female

0.94 (0.92-0.96)

White

Reference

Black

1.02 (0.99-1.05)

<0.23

1.03 (0.99-1.06)

<0.10

non-white nonblack
>=13% HG

0.82 (0.77-0.87)

<0.0001

0.86 (0.81-0.91)

<0.0001

1.12 (1.10-1.14)

<0.0001

1.07 (1.05-1.10)

<0.0001

<13% HG

Reference

Reference

>=$35,000

Reference

Reference

<$35,000

1.15 (1.12-1.17)

Urban

Reference

Rural

1.140 (1.06-1.22)

Academic

Reference

Community

1.20 (1.18-1.22)

Insured

Reference

Not insured

0.96 (0.90-1.03)

0

Reference

<0.0001

0.93 (0.91-0.94)

<0.0001

Reference

<0.0001

1.09 (1.07-1.12)

<0.0001

Reference
<0.0002

NS

0.150

Reference
<0.0001

1.20(1.17-1.22)

<0.0001

Reference
0.20

1.08 (1.01-1.16)
Reference

<0.024
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Charlson/Deyo
Score
Year of Diagnosis

Chemotherapy

Radiation Therapy

Immunotherapy

1

1.10 (1.08-1.12)

<0.0001

1.06 (1.04-1.09)

<0.0001

>=2

1.30 (1.26-1.35)

<0.0001

1.23 (1.19-1.28)

<0.0001

2004-2010

1.16 (1.13-1.18)

0.0001

1.16 (1.13-1.18)

0.0001

2011-2016

Reference

Reference

Yes

Reference

Reference

No

1.22 (1.19-1.24)

Yes

Reference

No

1.12 (1.10-1.14)

Yes

0.77 (0.70-0.85)

No

reference

<0.0001

1.14 (1.11-1.17)

<0.0001

Reference
<0.0001

1.03 (1.01-1.06)

<0.008

0.90 (0.81-0.99)
<0.0001

reference

<0.039

Table 9. Univariate and multivariate Cox analysis of Combining Immunotherapy with other treatments in patients who received
definitive surgery of the pancreatic tumor
Variable

Chemo and
immunotherapy
combination
Chemoradiation and
immunotherapy
combination

N (%)

Univariable analysis

Chemotherapy Only

21,198 (99.26%)

Hazard Ratio (95%
CI)
Reference

Chemo +
Immunotherapy
Chemoradiation Only

157 (0.74%)

0.82 (0.67-1.00)

21,424 (97.94%)

Reference

Multivariable analysis
P

Hazard Ratio (95%
CI)
Reference

P

<0.052

NS

0.44

Reference

Chemoradiation +
452 (2.06%)
0.80 (0.72-0.90)
<0.0001
0.85 (0.76-0.96)
Immunotherapy
Two different models were developed for the multivariable analysis of Table 6 because these variables were mutually exclusive

0.008
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Discussion
Using the NCDB, this study examined the impact of immunotherapy in combination with
chemotherapy and chemoradiation on the OS of PDAC patients who received definitive surgery
of the tumor. Chemoradiation but not chemotherapy alone plus immunotherapy was associated
with significantly improved OS in the univariate and multivariable Cox Proportional analysis
adjusted for age of diagnosis, gender, race, income, education treatment facility type,
Charlson/Deyo score, place of living, year of diagnosis, and insurance status.
The tumor microenvironment of PDAC is non-immunogenic and immunosuppressive87.
Pancreatic cancer itself induces local and systemic immune dysfunction or immunosuppression
to avoid being recognized and attacked by effector immune cells153,154. The tumor cells use
mechanisms such as the up-regulation of immune checkpoint signaling program ( PD-L1, CTLA4), the blockage of co-stimulation to activate T cells, and the recruitment of MDSCs, and tumorassociated macrophages to achieve immune suppression122,123,155. The tumor microenvironment
reflects a lack of tumor-infiltrating lymphocytes and dendritic cells and plenty of suppressor T
cells127,156. The immunosuppressive tumor microenvironment of PDAC is one of the reasons for
mono immunotherapy not to show the response and success in PDAC that has been reported in
many other malignancies42,149. However, various rational combination treatment strategies have
been proposed to overcome the resistance of PDAC to immunotherapy. The combination of
immunotherapies with chemotherapy and chemoradiation in PDAC represents a promising
strategy that could stimulate immunogenicity, improve antigen recognition, and inhibit tumormediated immunosuppression131,132.
Chemoradiation can work synergistically with immunotherapy and improve OS
compared to chemoradiation alone. Chemotherapy and RT cause the release of neoantigens and
upregulation of inflammatory cytokines, which promote the presentation of the neoantigens in
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the tumor microenvironment and thereby increase the immunogenicity of the tumor cells
making them better targets for immunotherapy137,140,157.
Checkpoint blockade immunotherapy has resulted in impressive responses in the
metastatic setting of various tumors and, more recently, has been tested in the adjuvant setting
after surgery127,156. FDA has approved a couple of checkpoint inhibitors for adjuvant use in
advanced melanoma, cervical cancer, bladder cancer, and renal cancer156,158. Various types of
immunotherapies, including checkpoint inhibitors and vaccines therapies in combination with
chemotherapy and chemoradiation, have been studied in early-stage and metastatic PDAC but
have not led to the FDA approval of immunotherapy for pancreatic cancer86. The use of
immunotherapy in neoadjuvant or adjuvant setting combined with chemoradiation in PDAC has
been limited. Some clinical trials studying the efficacy of immunotherapy in resectable PDAC
combined with chemoradiation therapy have shown positive response and measurable
activity80,159-161. More extensive studies are needed to confirm these findings.
Our results are consistent with the findings of a few other clinical trials and
retrospectives studies. A phase II trial involving 60 patients with resected PDAC, investigated the
impact of granulocyte-macrophage colony-stimulating factor (GM-CSF) with chemoradiation
reported a median survival of 24.8 months (95% CI, 21.2–31.6)80. A dose-escalating study with
24 patients evaluated Gene-mediated cytotoxic immunotherapy (GMCI™) in combination with
chemoradiation therapy for resected PDAC in adjuvant setting reported a median OS of 12
months and a 1-year OS of 50%160. A multi-institutional open-label phase II study evaluated
algenpantucel-L in combination with chemoradiation therapy in 70 patients with resectable
PDAC and reported the 12-months OS rate of 86%161. In the current study, we found a median
OS of 26.2 months, a 12-months OS rate of 88%, and a 24-months OS rate of 60% comparable to
these studies.
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To our knowledge, the current study is the first to use an extensive database such as
NCDB and investigate the impact of immunotherapy on the OS of PAD patients who receive
definitive surgery. In this study combining immunotherapy with chemoradiation was associated
with significantly improved OS. The results stayed the same when patients who received
immunotherapy more than six months before or after chemoradiation were excluded. The
findings of our study, together with early findings of some clinical trials, warrant future clinical
trials of immunotherapy combined with chemoradiation in PAD patients. Chemotherapy and
immunotherapy both induce a systemic immune response, and the addition of RT to
chemotherapy and immunotherapy may be required to overcome the local and systemic
immune suppression. The negative results of chemotherapy plus immunotherapy compared to
chemotherapy indicates that both systemic and local immune response is necessary to
overcome the immune evasion of pancreatic cancer cells. It is also possible that the number and
quality tumor-infiltrating T cells and neoantigens produced by chemotherapy are not enough for
immunotherapy to induce complete immune response as opposed to chemoradiation. The
immunostimulatory effect of chemotherapy, especially in the adjuvant setting is through the
inhibition of T regulatory cell and MDSCs rather than the stimulation and increase of T cells162164

. The significant improved OS associated with chemoradiation and immunotherapy is

biologically justified. Evidence indicates that chemoradiation, especially after surgery, can
significantly increase the number and function of dendritic cells by reducing immunosuppressive
cytokines165. Dendritic cells are an essential part of the immune system and play a critical role in
tumor cell recognition and T cells stimulation166. Chemoradiation is also capable of producing
humoral or cellular immune responses, and its combination with immunotherapy has shown to
mount long-term T cell reactivity74,85,167.
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The major strength of our study is the large sample size of the patients. The large
sample size enabled us to adjust for some important confounding factors. Our study has several
limitations. The NCDB, like many other large cancer databases, is prone to selection bias
affecting the receipt of immunotherapy. The database does not provide information about the
cause of death and the type of immunotherapy, such as checkpoint inhibitors and vaccine
therapy. The NCDB also does not collect information about the type of chemotherapy, and the
use of multi-agent chemotherapy regimens. Nonetheless, the NCDB is the largest cancer
database in the world which capture the majority of the newly diagnosed cancer cases in the
United States and serves as an excellent source outside of multicenter clinical trials for
examining the impact of novel treatments such immunotherapy on the OS of PDAC patients who
received definitive surgery of the tumor.

Conclusion
This study is the first large study with a robust analysis using the NCDB that has
investigated the impact of immunotherapy in combination with chemotherapy, RT, and
chemoradiation on the OS of PDAC patients who received definitive surgery of the tumor. In this
study, combining chemoradiation therapy with immunotherapy was associated with significantly
improved OS of the patients. The findings of the current study, together with the results of
other previous studies of the use of immunotherapy with other standard-of-care cancer
treatments in PDAC patients who receive surgery, warrant the need for future clinical trials of
investigating the impact of immunotherapy in this group of patients.
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CHAPTER 4
THE IMPACT OF THE SEQUENCE OF IMMUNOTHERAPY ON THE SURVIVAL OF
PANCREATIC ADENOCARCINOMA PATIENTS: A RETROSPECTIVE ANALYSIS OF THE
NATIONAL CANCER DATABASE

Abstract
Background: Immunotherapy has shown great success in various malignancies. However, its
efficacy in pancreatic ductal adenocarcinoma (PDAC) remains a challenge, and the lack of
understanding about the appropriate timing of immunotherapy with other standard-of-care
cancer treatments may be one of the causes. The objective of the current study is to investigate
the impact of the timing of immunotherapy with chemotherapy and RT on the overall survival
(OS) of PDAC patients who did not receive surgical resection of the pancreatic tumor. Materials
and methods: Patients with pancreatic adenocarcinoma who did not undergo surgical resection
of the pancreatic tumor were identified from the National Cancer Database (NCDB). Cox
proportional hazard models were employed to compare the OS between patients who received
immunotherapy with chemotherapy or RT with a different sequence of treatment. The
multivariable analysis was adjusted for age of diagnosis, race, sex, place of living, income,
education, treatment facility type, insurance status, and year of diagnosis. Results: In total, 705
patients received chemotherapy and immunotherapy, while 226 received radiation therapy and
immunotherapy. In the multivariable analysis, there was no significant difference in the OS of
patients who started immunotherapy 31-90 days before the start of chemotherapy (HR:1.06, CI:
0.72-1.56; p <0.78) and patients who started immunotherapy 91-180 days before the start of
chemotherapy (HR: 0.90, CI: 0.58-1.39; p <0.64) compared to patients who started
chemotherapy and immunotherapy within 30 days of each other. There was also no significant
difference in the OS of patients who started RT> 30 days before the start of immunotherapy
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(HR: 0.64, CI: 0.35-1.17; p <0.15) and patients who started immunotherapy > 30 days before the
start of RT (HR: 0.66, CI: 0.33-1.33; p <0.25) compared to patients who started RT and
immunotherapy within 30 days of each other. Conclusion: The sequence of immunotherapy
with chemotherapy or RT was not associated with improved OS. Future studies with a larger
subgroup sample size investigating the impact of the timing of immunotherapy with
chemotherapy and RT on the OS of PDAC patients who did not receive surgical resection of the
pancreatic tumor are needed.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents 3.2% of all cancer cases, but it is
responsible for 7.2% of all cancer deaths in the United States6. It is predicted that PDAC will
become the second leading cause of cancer deaths by 2030, after lung cancer168. The median 5year survival rate is 28-30% for localized diseases and only 8% for all stages. Due to the lack of
sensitive biomarkers for early detections, more than 80% of the patients present with a locally
advanced (non-resectable) disease169,170.
Surgery is the only curative treatment, but unfortunately, only 15-20 % of patients
present with cancer that is amenable to resection171. Resectable patients undergo curative
surgery followed by a combination of fractionated radiation therapy (RT) and chemotherapy as
adjuvant therapies, while unresectable patients receive chemotherapy or chemo-RT170. A
median OS of up to 54.4 months has been reported for patients with resectable PDAC who
receive modern adjuvant chemotherapy21. Nevertheless, a majority of the patients treated with
standard treatments eventually succumb to the disease and, due to the minimal effect of the
available treatments, new effective therapies for PC are urgently needed.
In recent years, immunotherapy has shown great success in various
malignancies, but is not approved by the FDA for the treatment of PDAC and is used in the clinic
as a last attempt after the failure of the current standard treatments172-178. Due to the negative
results of the mono immunotherapy trials in PDAC, most recent trials have focused on
combining immunotherapy with chemotherapy and RT43,49,60-62,95,96,113. Chemotherapy and RT
cause the release of neoantigens and upregulation of inflammatory cytokines, which are critical

69
for the optimal function of immune cells stimulated by immunotherapy137,139-141,157. The
preliminary findings of these trials have reported improved median OS for patients who
received immunotherapy with chemotherapy compared to historical data61,62,95,96. The sequence
of immunotherapy with chemotherapy and RT need to be balanced with the transient
immunosuppressive impact of chemotherapy and RT to achieve the optimal effect of the
combination. Chemotherapy and RT both cause a temporary increase in immunosuppressive
myeloid cells, circulating tumor-macrophages, depletion of T cells, and an increase in Treg cell,
which can suppress the immune system131,179,180.
In a previous study that is currently submitted for publication, we found that
immunotherapy combined with chemotherapy is associated with improved OS compared to
chemotherapy alone in PDAC patients who did not receive definitive surgery of the pancreatic
tumor. Improved OS was also noticed in patients who received chemoradiation plus
immunotherapy compared to chemoradiation without immunotherapy. There is no consensus
about the sequence of immunotherapy with RT, chemotherapy, and chemoradiation, and there
is no study that has investigated the sequence of immunotherapy with other cancer treatments
in PDAC as most of the trials of immunotherapy in PDA are in their early phases. The objective of
this study is to investigate the impact of the sequence of immunotherapy with chemotherapy,
and chemoradiation on the OS of PDAC patients using the National Cancer Database (NCDB) in
an attempt to determine the appropriate treatment sequence that could be used to mitigate the
immunosuppressive effects of the current treatments and maximize the impact of
immunotherapeutic.
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Methods
Data Source
The data for this study was obtained from the National Cancer Database (NCDB), which
is a joint program of the Commission on Cancer of the American College of Surgeons and the
American Cancer Society. The National Cancer Database is the largest in the world, and it
captures 70% or more of newly diagnosed malignancies in the United States annually. The
institutional review board evaluation was not obtained because the database provides deidentified data.
Study Population
Patients age 18 or older, diagnosed with PDAC between 2004 and 2016, were included
in the study. Patients who received definitive surgery of the primary pancreatic cancer and
those who had missing information on RT, chemotherapy, and immunotherapy were excluded.
Patients with unknown or missing information about other covariates were not included in the
adjusted multivariable analysis. The chemotherapy plus immunotherapy treatment sequence
was divided into chemotherapy and immunotherapy within 30 days of each other,
immunotherapy 31-90 days before chemotherapy, and immunotherapy 91-180 days before
chemotherapy. There was not enough sample for chemotherapy >30 days before
immunotherapy. The RT and immunotherapy treatment sequences were divided into RT and
immunotherapy within 30 days of each other, 30 <RT <=180 days before immunotherapy, and
30<immunotherapy <=180 days before RT. Patients who started immunotherapy > 6 months
before chemotherapy were excluded. Patients who started RT >6 months before
immunotherapy or immunotherapy >6 months before RT were also excluded
End Points

71
The primary outcome of the current study was overall survival (OS), which was
calculated from the date of diagnosis to the date of death from any cause. Those alive or lost to
follow up were censored at the date of the last contact. We also reported the treatment
patterns related to the use of immunotherapy.
Statistical Analyses
Descriptive statistics for categorical and continuous variables are reported. The
association of various demographic and tumor-related factors with the type of treatment
sequence was tested using the chi-square test of association. Kaplan-Meier curves and log-rank
tests were utilized to report the difference in median OS between the treatment sequences.
Multivariable Cox analysis was conducted to assess the OS of patients. The estimated hazard
ratios with associated 95% confidence intervals (CI) were reported. A P-value of 0.05 was
considered for a significant level. The SAS 9.4 software was used for the analysis.

Results
Chemotherapy and immunotherapy with or without RT
In total, 705 patients were eligible for the final analysis of this group. Among them,
621/705 (88.09%) started chemotherapy and immunotherapy within 30 days of each other,
41/705 (5.82%) started immunotherapy 31-90 days before the start of chemotherapy, and
43/705 (6.10%) started immunotherapy 91-180 days before the starting chemotherapy. Among
621 patients who started chemotherapy and immunotherapy within 30 days of each other
470/621 (75.68%) started the two treatments on the same day, 525/621 (84.54%) started within
two days, and 551/621 (88.57%) started within seven days of each other. The last two
proportions are cumulative.
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The median age of diagnosis for the entire cohort was 64.00, with a range of 21-90
years. The median age of the diagnosis was 64.00 (21-90) years for patients who started
chemotherapy and immunotherapy within 30 days of each other, 65.00 (44-83) years for the
group who started immunotherapy 31-90 days before chemotherapy, and 64.00 (40-79) years
for patients who started immunotherapy 91-180 days before chemotherapy. The majority of the
patients were White, had high school degrees, had income >=$35,000, were insured, living in
the urban areas, were treated in academic hospitals, and had a comorbidity score of zero. There
was no association between the baseline characteristics of the patients and the treatment
sequence except the hospital type and the year of diagnosis. Among patients who started
chemotherapy and immunotherapy within 30 days of each other, 63.93% were treated at
academic facilities. In patients who started immunotherapy 31-90 days before the start
chemotherapy, 46.34% were treated at academic hospitals. In comparison, 72.09% of the
patients who started immunotherapy 91-180 days before the start of chemotherapy were
treated at academic hospitals. The proportion of patients who were diagnosed in 2011 and later
were 46.22%, 63.41%, and 83.72% for those who started chemotherapy and immunotherapy
within 30 days of each other, started immunotherapy 31-90 days before chemotherapy, and
those who started immunotherapy 91-180 days before the start chemotherapy. The baseline
characteristics are provided in Table 10.
Based on the KM curves, the OS of the treatment categories was not significantly
different from each other (Figure 3). The median OS was 10.68 (CI: 9.79-11.66) months for
patients who started chemotherapy and immunotherapy within 30 days of each other, 7.82 (CI:
5.85-11.93) months for patients who began immunotherapy 31-90 days before the start of
chemotherapy, and 9.72 (6.67-14.62) months for patients who started immunotherapy 91-180
days before the start of chemotherapy Table 11.
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In the multivariable Cox Proportional analysis (Table 12) adjusted for the age of
diagnosis, sex, race, education, income, hospital type, comorbidity score, and year of diagnosis,
there was no significant difference in the OS of patients who started immunotherapy 31-90 days
before the start of chemotherapy (HR:1.06, CI: 0.72-1.56; p <0.781) compared to patients who
started chemotherapy and immunotherapy within 30 days of each other. There was also no
difference in the OS of patients who started immunotherapy 91-180 days before the start of
chemotherapy (HR: 0.90, CI: 0.58-1.39; p <0.64) compared to patients who started
chemotherapy and immunotherapy within 30 days of each other. The 1-year survival rates were
44% (CI: 40%-48%) for patients who started chemotherapy and immunotherapy within 30 days
of each other, 32% (CI: 16%-48%) for those who started immunotherapy 31-90 days before
starting chemotherapy, and 38% (CI: 20%-56%) for patients who started immunotherapy 91-180
days before beginning chemotherapy.
Radiation therapy and immunotherapy with or without chemotherapy
Among the 226 patients who received RT and immunotherapy, 177/226 (78.32%)
started RT and immunotherapy within 30 days of each other, 34/226 (15.04%) started RT > 30
days before starting immunotherapy, and 15/226 (6.64%) started immunotherapy > 30 days
before starting RT. Importantly, among those who began Rt and immunotherapy within 30 days
of each other, 107/177 (60.45% ) started the two treatment on the same day, 140/177 (79.66%)
started the two treatments within 2 days from each other, and 153/177 (86.44%) patients
started the two treatment within a week of each other indicating a pattern of care that clinicians
are in favor of administrating the two treatment close to each other.
The median age of this cohort was 62.0 (33-85) years. The median age of those who
started RT and immunotherapy within 30 days of each other was 61.0 (33-85), while the median
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age of the patients who started RT > 30 days before starting immunotherapy was 64.0 (80-37)
years, and patients who received immunotherapy > 30 days before the start of RT was 70.0 (4780). Except for hospital type, comorbidity score, and year of diagnosis, no other variables were
associated with the treatment sequence of RT and immunotherapy. Among patients who
started RT and immunotherapy within 30 days of each other, 78.29%% were treated at
academic hospitals, while 75.76% of the patients who started RT > 30 days before
immunotherapy and 33.33% of patients who started immunotherapy > 30 days before RT were
treated at academic hospitals. Among the patients who started RT and immunotherapy within
30 days of each other, 84.18% had comorbidity score of zero, while 73.53% of the patients who
started RT> 30 days before the start of immunotherapy, and 46.47% of the patients who started
immunotherapy > 30 days before the start of RT had comorbidity score of zero.
Among the patients who started RT and immunotherapy within 30 days of each other
only 16.38% were diagnosed between 2011 and 2016, while 85.29% of the patients who started
RT> 30 days before the start of immunotherapy, and 60.00% of the patients who started
immunotherapy > 30 days before the start of RT were diagnosed between 2011 and 2016.
The characteristics of the patients are shown in Table 13. Based on KM, there was no
significant difference in the median OS of the treatment sequence groups (Figure 4; p=0.497).
The median OS was 12.39 (CI: 10.84-13.54) months for patients who started RT and
immunotherapy within 30 days of each other only, 13.27 (CI: 11.20-19.19) months patients who
started RT> 30 days before the start of immunotherapy, and 8.54 (CI: 5.09-15.67) months
patients who started immunotherapy > 30 days before the start of RT (Table 14).
In the multivariable analysis, there was no significant difference in the OS of patients
who started RT> 30 days before the start of immunotherapy (HR: 0.64, CI: 0.35-1.17; p=0.15)
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compared to patients who started RT and immunotherapy within 30 days of each other. The OS
was also not different between patients who started immunotherapy > 30 days before the start
of RT (HR: 0.66, CI: 0.33-1.33; p=0.25) compared to patients who started RT and
immunotherapy within 30 days of each other (Table 15). The 1-year survival rates were 51% (CI:
44%-59%) for patients who started RT and immunotherapy within 30 days of each other, 43%
(CI: 17%-69%) for those who began immunotherapy > 30 days before beginning RT, and 62%
(CI: 61%-79%) for patients who started RT > 30 days before starting RT.

Discussion
To our knowledge, the current study is the first and the most extensive research on
reporting treatment patterns in the use of immunotherapy and comparing the impact of the
timing of immunotherapy with chemotherapy and RT in PC patients who did not get definitive
surgery of the pancreatic tumor.
This study provides information about the timing pattern of immunotherapy treatment
in PDAC patients. The findings indicate that the majority of patients receive immunotherapy
within 30 days of chemotherapy or RT. The results also suggest that clinicians tend to start
immunotherapy close to the start of chemotherapy or RT. As noticed, the majority of the
patients began immunotherapy on the same day with starting chemotherapy or RT. Current
clinical guidelines favor the concurrent use of immunotherapy with chemotherapy or RT.
However, starting immunotherapy on the same day with chemotherapy or RT may not deliver
the optimal benefits as chemotherapy, and RT both cause transient immunosuppression.
Starting immunotherapy during that window of systemic and local immunosuppression may
minimize the synergetic effect of the interaction of immunotherapy with chemotherapy and RT.
The majority of the patients who received immunotherapy with 30 days of chemotherapy or RT
were treated at academic centers, and these centers tend to recommend the concurrent use of
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immunotherapy with chemo and RT. Current ongoing clinical trials which some of these centers
may be participating in are also administering the concomitant use of immunotherapy with
other treatments. Data are lacking to either confirm or oppose the current treatment sequence
used in these clinical trials.
In the current study, the treatment sequence of immunotherapy with chemotherapy
and RT was not associated with improved OS. In our unpublished data, we found that
immunotherapy is associated with improved OS when combined with chemotherapy or
chemoradiation. Based on the findings of that data, we decided to investigate the timing of
immunotherapy with other cancer treatments and see if the timing of immunotherapy matters.
However, the results of the current study indicate that the improved OS associated with the use
of immunotherapy in combination with chemotherapy or chemoradiation therapy does not
depend on the sequence of the treatments.
The optimal time of immunotherapy may depend on the mechanism of the
immunotherapy drug and the cancer type181. For example, a preclinical study of colorectal
carcinoma found that the optimal timing for the anti-CTLA4 blockade is before RT, while for antiOX40 agonists, the best time is after RT182. These findings have been supported by clinical
studies and case series of metastatic melanoma, gastrointestinal cancers, NSCLC, lymphoma,
and head and neck cancer patients in which patients received immunotherapy first and then
received RT or chemotherapy183-189. Contrarily a few other studies which only included brain
metastasis (BMs) patients from melanoma reported better results when SRS was administered
either before immunotherapy or concurrently190-193. Patients with BMs from melanoma who
received whole-brain RT plus SRS before ipilimumab had better median OS compared to
ipilimumab before SRS or concurrently with [26 vs. six vs. 18] months190.
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Nonetheless, the majority of these studies were not designed to investigate the
treatment sequence due to the absence of comparison group, had small sample size, only
looked into SRS or RT in BMs, and only included ipilimumab. Current ongoing clinical trials are
designed to deliver immunotherapy concurrently with RT or after RT, ignoring the reports that
giving anti-CTLA4 before palliative RT may improve response rate194,195.
The negative results of the study may be in part due to the small sample size of some of
the treatment sequence groups, especially for immunotherapy plus RT cohort. The insignificant
results of the sequence of RT with immunotherapy may be due to the use of a low dose of
conventional RT fraction in most of these patients. The majority of the patients received
conventional RT with 1.8-2 Gray per fraction, and past reports have suggested that higher
fractional doses such as those provided with SBRT are required to improve immunotherapy
when combined with RT. It is also possible that the benefit of immunotherapy with RT is
drowned by using immunotherapy with chemo and vice versa. It is also possible that the
sequence of immunotherapy with other treatments such as chemotherapy and RT does not
matter, and immunotherapy is associated with improved OS, as found in our unpublished data.
Our findings are consistent with the results of other studies in which there was no difference in
the OS of BMs patients when RT was delivered before immunotherapy or after immunotherapy
or if RT was administered concurrently with immunotherapy or sequentially 196-198.
The strength of this study is the relatively large sample size, which allows for adjusting
for various critical patient and tumor-related factors. However, the study is not without several
limitations. The limitations include selection bias, lack of information on the cause of death, lack
of information about the type of immunotherapy, and if a single or combined immunotherapy
was administered, and lack of detailed information on the use of multi-agent chemotherapy.
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The small sample size for some treatment sequence groups in both immunotherapy plus
chemotherapy and immunotherapy plus RT was another limitation of the study.

Conclusion
To our knowledge, the current study is the first and the most extensive research that
has compared the timing of immunotherapy with chemotherapy and RT. There was no
association between the treatment sequence of immunotherapy with chemotherapy or RT and
the OS of the patients. Future studies with a large sample size for each subgroup of the
treatment sequences are needed to investigate the timing of immunotherapy with
chemotherapy and RT.
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Figure 3. Overall survival of unresectable PDAC patients chemotherapy plus immunotherapy
regardless of RT; chemotherapy and immunotherapy started within 30 days of each other
(blue), immunotherapy started 31-90 days before chemotherapy (red), immunotherapy started
91-180 days before chemotherapy (green)

Figure 4. Overall survival of unresectable PDAC patients with RT plus immunotherapy regardless
of chemotherapy: RT and immunotherapy started within 30 days of each other (blue),
immunotherapy started >30 days before the start of radiation therapy (red), radiation therapy
started > 30 days before the start of chemotherapy (green)
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Table 10. Baseline characteristics of the sequence of immunotherapy with chemotherapy in PDAC patients with no surgery
Variable

CTx and Immx within 30 days

Immx 31-90 days bf

Immx 91-180 days bf

Total 705

Age at diagnosis (mean)

of each other 621 (88.09%)
64.0 (21-90)

CTx 41 (5.82%)
65.0 (44-83)

64.0 (21-90)

Male

354 (57.00)

24 (58.54)

CTx
64.0 (40-79)
43 (6.10%)
23 (53.49)

Female

267 (43.00)

17 (41.46)

20 (46.51)

304 (43.12)

White

538 (87.48)

37 (90.24)

40 (95.24)

615 (88.11)

Black

56 (9.11)

3 (7.32)

1 (2.38)

60 (8.60)

Other

21 (3.41)

2.44

1 (2.38

23 (3.30)

Unknown

6

0

1

7

>=13% HG

216 (35.06)

11 (27.50)

10 (23.26)

237 (33.91)

<13%

400 (64.94)

29 (72.50)

33 (76.74

462 (66.09)

Unknown

5

1

0

6

>=$35,000

402 (65.26)

28 (71.79)

29 (67.44)

459 (65.76)

<35,000

214 (34.74)

11 (28.21)

14 (38.56)

239 (34.24)

Unknown

5

2

0

7

Urban

587 (97.83)

38 (97.44)

42 (100.00)

667 (97.94)

Rural

13 (2.17)

1 (2.56)

0 (0.00)

14 (2.06)

Unknown

21

2

1

24

Academic

390 (63.93)

19 (46.34)

31 (72.09)

440 (63.40)

Community

220 (36.07)

22 (53.66)

12 (27.91)

254 (36.60)

Sex

Race

Education

Income

Living place
Hospital Type

401 (56.88)

P

0.88

0.62

0.19

0.69

0.62

0.037
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Insurance

Charlson Score

Year of Diagnosis

CTx=chemotherapy

Unknown

11

0

0

11

Yes

572 (89.45)

40 (97.56)

39 (97.50)

651 (98.34)

No

9 (10.55)

1 (2.44)

1 (2.50)

11 (1.66)

Unknown

41

0

2

43

0

486 (78.26)

30 (73.17)

34 (79.07)

550 (78.01)

1

108 (17.39)

8 (19.51)

8 (18.60)

124 (17.59)

>=2

27 (4.35)

3 (7.32)

1 (2.33)

31 (4.40)

2004-2010

334 (53.78)

15 (36.59)

7 (16.28)

356 (50.50)

2011-2016

287 (46.22)

26 (63.41)

36 (83.72)

349 (49.50)

Immx=immunotherapy bf=before

Table 11. Median OS of chemotherapy and immunotherapy sequence groups
Variable

Median OS (95% CI)

Chemotherapy and immunotherapy within 30 days of each other

10.68 (9.79-11.66)

Immunotherapy 31-90 days before chemotherapy

7.82 (5.85-11.93)

Immunotherapy 91-180 days before chemotherapy

9.72 (6.67-14.62)

0.83

0.83

0.0001
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Table 12. Univariate and multivariable Cox analysis of the sequence of chemotherapy and immunotherapy in PDAC patients with no
surgery
Variables

Univariate Analysis
HR (95% CI)

CT plus immunotherapy

Multivariable Analysis
P

HR (95% CI)

P

CTx and Immx within 30 days

Ref

Ref

Immx 31-90 days before CTx

1.18 (0.82-1.71)

0.38

1.06 (0.72-1.56)

0.78

Immx 91-180 days before CTX

0.90 (0.61-1.33)

0.60

0.90 (0.58-1.39)

0.64

Table 13. Baseline characteristics of the sequence of radiation therapy with immunotherapy in PDAC patients with no surgery
Variable

RT and Immx within 30 days of

Immx >30 days before RT

RT>30 days before Immx

Total

Age at diagnosis (mean)

each other 177 (78.32)
61.0 (33-85)

15 (6.64)
70.0 (47-80)

34 (15.04)
64.0 (80-37)

226
62.0 (33-85)

Male

99 (55.93)

10 (66.67)

15 (44.12)

124 (54.87)

Female

78 (44.07

5 (33.33)

19 (55.88)

102 (45.13)

White

154 (89.53)

12 (80.00)

29 (85.29)

195 (88.24)

Black

12 (6.98)

2 (13.33)

5 (14.71)

19 (8.60)

Other

6 (3.49)

1 (6.67)

0 (0.00)

7 (3.17)

Unknown

5

0

0

5

>=13% HG

58 (32.95)

7 (46.67)

11 (32.35)

76 (33.78)

Sex

Race

P

0.29

0.37

0.55
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Education

<13%

118 (67.05)

8 (53.33)

23 (67.65)

149 (66.22)

Unknown

1

0

0

1

>=$35,000

123 (69.89)

8 (53.33)

24 (70.59)

155 (68.89)

<35,000

53 (30.11)

7 (46.67)

10 (29.41)

70 (31.11)

Unknown

1

0

0

1

Place of

Urban

168 (97.67)

15 (100.00)

33 (100.00)

216 (98.18)

Living

Rural

4 (2.33)

0 (0.00)

0 (0.00)

4 (1.82)

Unknown

5

0

1

6

Academic

137 (78.29)

5 (33.33)

25 (75.76)

167 (74.89)

Community

38 (21.71)

10 (66.67)

8 (24.24)

56 (25.11)

Unknown

2

0

1

3

Yes

148 (98.67)

14 (100.00)

33 (97.06)

195 (98.48)

No

2 (1.33)

0 (0.00)

1 (2.94)

3 (1.52)

Unknown

27

1

0

28

Charlson

0

149 (84.18)

7 (46.67)

25 (73.53)

181 (80.09)

Score

1

23 (12.99)

5 (33.33)

8 (23.53)

36 (15.93)

>=2

5 (2.82)

3 (20.00)

1 (2.94)

9 (3.98)

2004-2010

148 (83.62)

6 (40.00)

5 (14.71)

159 (70.35)

9 (60.00)

29 (85.29)

67 (29.65)

Income

Hospital Type

Insurance

Year of

2011-2016
29 (16.38)
Diagnosis
RT=radiation therapy Immx=immunotherapy bf=before

0.40

0.57

0.0006

0.70

0.001

0.0001
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Table 14. Median OS of RT and immunotherapy sequence groups
Variable

Median OS (95% CI)

RT and immunotherapy within 30 days of each other

12.39 (10.84-13.54)

RT > 30 days before immunotherapy

13.27 (11.20-19.19)

Immunotherapy > 30 days before RT

8.54 (5.09-15.67)

Table 15. Univariate and multivariable Cox analysis of the sequence of radiation therapy and immunotherapy in PC patients with no
surgery
Variables

Univariate Analysis
HR (95% CI)

Radiation therapy plus
immunotherapy

Multivariable Analysis
P

HR (95% CI)

P

RT and Immx within 30 days

Ref

Ref

RT >30 days bf Immx

0.71 (0.47-1.09)

0.11

0.63 (0.35-1.17)

0.146

Immx >30 days bf RT

1.17 (0.66-2.06)

0.59

0.66 (0.33-1.33)

0.245
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CHAPTER 5
THE IMPACT OF NEOADJUVANT AND ADJUVANT IMMUNOTHERAPY ON THE SURVIVAL
OF PANCREATIC CANCER PATIENTS: A RETROSPECTIVE ANALYSIS

Abstract
Background: Immunotherapy has become an essential part of cancer treatment after showing
excellent efficacy in various malignancies. However, its effectiveness in pancreatic
adenocarcinoma (PDAC), especially in resectable pancreatic cancer, has not been studied. The
primary objective of this study is to compare the OS impact of immunotherapy between PDAC
patients who receive neoadjuvant immunotherapy and patients who receive adjuvant
immunotherapy. The secondary aim is to investigate the impact of neoadjuvant and adjuvant
immunotherapy in combination with chemotherapy and chemoradiation by performing subsets
analyses of these two groups. Methods: Patients diagnosed with PDAC between 2004 and 2014
were identified from the National Cancer Database (NCDB). Multivariable Cox proportional
hazard analysis was performed to examine the difference in the OS of patients who received
adjuvant and neoadjuvant immunotherapy in combination with chemotherapy and
chemoradiation. The multivariable analysis was adjusted for essential factors such as the age of
diagnosis, sex, race, education, income, place of living insurance status, hospital type,
comorbidity score, and year of diagnosis was used to assess the OS of the patients. Results:
Overall, 526 patients received immunotherapy, among whom 408/526 (77.57%) received
neoadjuvant immunotherapy, and the remaining 118/526 (22.43%) received adjuvant
immunotherapy. Neoadjuvant immunotherapy was not associated with improved OS (HR: 1.10,
CI: 0.79-1.41; p=0.71) compared to adjuvant immunotherapy in the multivariable analysis. In the
subset analysis of neoadjuvant and adjuvant therapies patients, immunotherapy combined with
chemotherapy or chemoradiation was not associated with improved OS compared to
chemotherapy or chemoradiation without immunotherapy. Conclusion: In this study, no
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difference in the OS between patients who received neoadjuvant immunotherapy and patients
who received adjuvant immunotherapy was noticed. Future studies comparing neoadjuvant
adjuvant immunotherapy combined with chemotherapy, radiation therapy, and chemoradiation
are needed.
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Introduction
The majority of pancreatic cancer (PC) patients are diagnosed with unresectable PC,
while less than 20% are diagnosed with resectable cancer19,199. The current standard-of-care
treatment for resectable PC is upfront surgery followed by adjuvant single or combined
chemotherapy200. The median overall survival (OS) after surgery is between 15-24 months with a
five-year survival rate of 20% with some recent data showing a median OS of up to 54
months21,201-203. Up to 80% of patients who undergo surgery experience recurrence, owing
significantly to micrometastases, which occur early in the disease, or microscopic residual
disease in the tumor bed19,199. These difficulties have brought adjuvant therapy to the forefront
of PC treatment. Despite the improvement in surgical techniques, radiation therapy (RT), and
chemotherapeutic options, only a modest increase in the OS has been noticed204. Due to the
lack of current standard-of-care treatments, novel treatment strategies such as the use of
immunotherapeutics are desperately needed.
Immunotherapy has worked well in many solid cancers, but its use in PC is not clear42,149.
The use of immunotherapy to date has been mainly in the metastatic setting. However, new
evidence indicates that immunotherapy could be useful in patients with localized disease who
have a high risk of micrometastases22,86,102-105. Chemotherapy and RT increase tumor-specific T
cell infiltration, decrease T regulatory cells, and suppress Myeloid-derived suppressor cells
(MDSCs), and can have synergistic interaction with immunotherapy22,88,129. Immunotherapy was
associated with tumor regression and improved OS in preclinical studies of PDAC when used in
combination with other treatments89,90. To achieve the optimal OS effect of the use of
immunotherapy with chemotherapy and chemoradiation in PC, the sequence of the treatment is
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critical. The sequence of treatment even becomes more important in resectable PS due to the
potential interactions of systemic therapy with surgery. Due to the higher rate of recurrence
after surgery, the early implementation of systemic therapy is needed205.
Neoadjuvant treatment (NAT) strategies have emerged and been employed as an
attractive option for resectable and potentially resectable PC206,207. Neoadjuvant treatment can
also turn those initially borderline resectable or even some unresectable disease into
resectable206,207. This strategy provides an opportunity for an early start of systemic therapy in
contrast to upfront surgery, where more than half of the patients may not receive adjuvant
therapy due to postoperative complications and declining performance status208-210. Recent
clinical trials and systematic reviews have reported the survival benefit of NAT211-214. However,
the effectiveness of NAT in resectable PC remains unclear as there are still many questions to be
addressed before NAT become a standard of care215.
The neoadjuvant and adjuvant use of immunotherapy both could be justified.
Neoadjuvant immunotherapy with chemotherapy or chemoradiation could shrink the tumor,
downstage nodal disease, and increase the chance of margin negative resection as reported for
neoadjuvant systemic therapy216,217. It may also work with chemotherapy or chemoradiation to
mitigate the risk of micrometastases218,219. Conversely, adjuvant immunotherapy may be useful
when the bulk of the tumor is removed, and there is a minimal residual disease, which T cells
can target and eliminate. Also, the timing of adjuvant immunotherapy needs to be appropriately
chosen as surgery is associated with transient immunosuppression220,221. The use of
immunotherapy in neoadjuvant or adjuvant setting combined with chemoradiation in PDAC has
been limited. Some clinical trials studying the efficacy of immunotherapy in resectable PDAC
combined with chemoradiation therapy have shown positive response and measurable
activity80,159-161. However, large studies of neoadjuvant and adjuvant immunotherapy in
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resectable PC are lacking. The objective of this study is to investigate the impact of neoadjuvant
and adjuvant immunotherapy in combination with chemotherapy and chemoradiation on the
OS of resectable PDAC patients using the National Cancer Database (NCDB).

Methods
Data source
The data for this study was extracted from a de-identified file of the National Cancer
Database (NCDB). The NCDB is a joint program of the Commission on Cancer of the American
College of Surgeons and the American Cancer Society. It captures 70% or more of newly
diagnosed malignancies in the United States annually. This study was exempt from the
Institutional Review Board (IRB) because the de-identified data were used.
Study population
The study included patients age 18 or older who were diagnosed with PADC between
2004 and 2016 and received definitive surgery of the tumor. The ICD-O-3 histology codes of
8000, 8010, 8020-8022, 8140, 8141, 8211, 8230, 8500, 8521, 8050, 8260, 8441, 8450, 8453,
8470-8473, 8480, 8481, 8503,8250,8440, 8560 were used to identify PADC. The surgical sitespecific code was used to identify patients with definitive surgery of the pancreas. Patients who
were missing information about RT, chemotherapy, immunotherapy, and sequence of these
treatments with each other and surgery were excluded. Patients with the M1 stage and those
with unknown or missing information about other covariates in the adjusted multivariable
analysis were also excluded. The analysis of the sequence of immunotherapy with RT alone was
not performed due to the small sample size. The variable of days from diagnosis to the start of
the treatment was used to identify neoadjuvant and adjuvant immunotherapy, chemotherapy,
and chemoradiation. If chemotherapy, RT, and immunotherapy were delivered more than eight
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months before or after surgery, those patients were excluded. If immunotherapy was received
more than six months before or after chemotherapy or RT, those patients were also excluded.
The primary outcome of the current study was the OS of the patients, which was calculated
from the date of diagnosis to the date of death. Patients who were alive or lost to follow up
were censored. The subset analysis of the neoadjuvant group only included patients who
received only neoadjuvant chemotherapy, immunotherapy, RT, and chemoradiation. If any of
the treatment was not neoadjuvant, they were excluded for this subset analysis. Patients with
no treatment were also excluded. The subset analysis of adjuvant treatment comparison
included patients who only received adjuvant chemotherapy, immunotherapy, RT, and
chemoradiation. If any of the treatment was not adjuvant, those patients were excluded for
adjuvant subset analysis. Patients with no treatment were also excluded from this subset
analysis.
Explanatory variables
The main predictors of OS in this study were immunotherapy combined with
chemotherapy, and immunotherapy combined with chemoradiation. The age of diagnosis,
gender, race, urban and rural living status, income, education, treatment facility type,
comorbidity score, insurance status, year of diagnosis, and receipt of chemotherapy, RT, and
immunotherapy were other explanatory variables used in the multivariable analysis.
Statistical analyses
Descriptive statistics for categorical and continuous variables are reported. A Chi-square
test was used to report the association of the explanatory variables with the treatment
sequence of immunotherapy with chemotherapy and chemoradiation therapy. The difference in
the median OS between the different treatment sequences was reported using the Kaplan-
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Meier curves based on the log-rank test. The Cox proportional analysis was used to determine
the OS of the patients. The estimated hazard ratio (HR) with its associated 95% confidence
intervals (CI) was reported. A p-value of 0.05 was considered significant which based on the twoside t-test. The analysis was conducted using the SAS 9.4 software.

Results
Neoadjuvant immunotherapy vs. adjuvant immunotherapy. Among 526 patients who
received immunotherapy, 408/526 (77.57%) received neoadjuvant immunotherapy, and the
remaining 118/526 (22.43%) received adjuvant immunotherapy. The median age of diagnosis
among patients who received immunotherapy was 62 with a range of (29-88) years. The median
age of diagnosis of patients who received neoadjuvant immunotherapy was 62.0 (34-88) years,
while it was 62.5 (29-86) years in patients who received adjuvant immunotherapy. A majority of
the patients were White, living in the urban areas, had a high school degree, had income
>=$35000, had insurance, were treated in academic hospitals, and had a Charlson/Deyo Score of
zero. There was no association between the baseline characteristics of the patients and
receiving neoadjuvant or adjuvant immunotherapy except the year of diagnosis. Among patients
who received neoadjuvant immunotherapy, 41.67% were diagnosed after 2011, while among
patients who received adjuvant immunotherapy, 66.10% were diagnosed after 2011. Among
those diagnosed after 2011, 68.55% received neoadjuvant immunotherapy compared to 31.45%
who received adjuvant immunotherapy, while among those who were diagnosed before 2011,
85.61% received neoadjuvant immunotherapy compared to 14.39% who received adjuvant
immunotherapy. The baseline characteristics of the study population are shown in Table 16. We
did not report the baseline characteristics of the neoadjuvant and adjuvant subsets analyses due
to insignificant results of these subsets.
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The KM curves did not show any significant difference in the median OS of patients who
received neoadjuvant immunotherapy compared to adjuvant immunotherapy (Figure 5). The
median OS of patients who received neoadjuvant immunotherapy was 26.78 months (CI: 23.9231.24) vs. 34.37 months (CI: 24.21-42.28 months; p=703) in patients who received adjuvant
immunotherapy. In the multivariable Cox analysis, neoadjuvant immunotherapy was not
associated with improved OS (HR: 1.10, CI: 0.79-1.41; p=0.71) compared to adjuvant
immunotherapy (Table 17).

Subset analyses
Only neoadjuvant subset analysis. This group was restricted to patients who only
received neoadjuvant treatments such as chemotherapy, RT, chemoradiation, and
immunotherapy. If any of the treatment was not neoadjuvant, those observations were
excluded from this subset analysis. Based on KM curves, patients who received neoadjuvant
immunotherapy had significantly improved OS with an absolute median OS benefit of 2.6
months compared to patients who did not receive immunotherapy (25.10 months, CI: 21.4227.96 vs. 22.51 months, CI: 22.21-22.77) (Figure 6a). There was no difference in the median OS
of patients who received neoadjuvant chemotherapy plus immunotherapy compared to
neoadjuvant chemotherapy alone (Figure 6b), and patients who received neoadjuvant
chemoradiation plus immunotherapy compared patients who received only neoadjuvant
chemoradiation (Figure 6c). In the univariate Cox proportional analysis, neoadjuvant
immunotherapy was associated with improved OS (HR: 0.88, CI: 0.78-0.98; p <0.026) compared
to no immunotherapy. However, in the multivariable analysis, this association became
nonsignificant (Table 18). In the multivariable analysis, there was no difference in the median OS
of patients who received neoadjuvant chemotherapy plus immunotherapy compared to
neoadjuvant chemotherapy alone ( HR: 0.93, CI: 0.73-1.20; p=0.97) and patients who received
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neoadjuvant chemoradiation plus immunotherapy compared to neoadjuvant chemoradiation
alone (HR: 0.94, CI: 0.81-1.09; p=0.425) (Table 18).

Adjuvant subset. This analysis included patients who only received adjuvant
chemotherapy, RT, chemoradiation, and immunotherapy. If any of the treatment was not
adjuvant, those patients were not included in this subset analysis. Based on KM curves, there
was no difference in the median OS of patients who received adjuvant immunotherapy
compared to patients who received other adjuvant treatment but did not receive
immunotherapy (Figure 7a). There was no difference in the median OS of patients who received
adjuvant chemotherapy plus immunotherapy or chemoradiation plus immunotherapy compared
chemotherapy or chemoradiation without immunotherapy (Figure 7b). In the multivariable
analysis, there was no significant difference in the OS of patients who received adjuvant
immunotherapy compared to no immunotherapy (HR:1.00, CI: 0.76-1.32; p=0.99). A significant
difference in the OS was also not observed between patients who received adjuvant
chemotherapy plus immunotherapy or chemoradiation plus immunotherapy compared
chemotherapy or chemoradiation without immunotherapy (HR: 1.01, CI: 0.75-1.37; p= 0.94)
(Table 19). The adjuvant chemotherapy plus immunotherapy group was combined with
chemoradiation plus immunotherapy due to a small sample size.

Discussion
To our knowledge, the current study is the most extensive study that has compared the
impact of neoadjuvant immunotherapy vs. adjuvant immunotherapy on the OS of PDAC patients
who received definitive surgery of the pancreatic tumor. There was no significant difference in
the median OS of patients who received neoadjuvant immunotherapy compared to patients
who received adjuvant immunotherapy. However, in the neoadjuvant subset analysis,
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immunotherapy was associated with significantly improved OS compared to no immunotherapy
in the univariate analysis though this significance was lost upon multivariable analysis.
The tumor cells use mechanisms such as the up-regulation of immune checkpoint
signaling programmed death-ligand 1 (PD-L1), downregulation of cytotoxic T-lymphocyteassociated protein 4 (CTLA4), and the recruitment of MDSCs, to evade the immune system125-127.
Immunotherapy, especially checkpoint inhibitors, down-regulates the PD-L1 pathway and
upregulates anti-CTLA486,88. The insignificant results of neoadjuvant immunotherapy compared
to adjuvant immunotherapy may indicate that the impact of immunotherapy on the OS of PC
patients who receive definitive surgery of the pancreatic tumor is not related to the sequence of
immunotherapy with surgery. Our unpublished data found that immunotherapy was associated
with improved OS compared to no immunotherapy indicating the potential benefit of
immunotherapy in these patients. In that study, the sequence of the treatment was not studied.
A small sample size of group comparisons in the neoadjuvant and adjuvant subsets analyses may
be responsible for insignificant results.

Limitations
The large sample size for the comparison of neoadjuvant immunotherapy vs. adjuvant
immunotherapy is the most important strength of the current study, which allowed us to adjust
for patient and tumor characteristics. However, the study is not without limitations, most of
which are inherent to NCDB and include selections bias, lack of information of the cause of
death, lack of information about the type of immunotherapy and if a single or combined
immunotherapy was administered, and lack of detailed information on the use of multi-agent
chemotherapy. One other limitation was that due to the small sample size for immunotherapy
plus RT, the sequence of immunotherapy with RT alone was not performed. Also, there were
not enough cases for adjuvant comparison, and that maybe one of the reasons that we failed to
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find any significant difference in the OS of patients who received adjuvant immunotherapy,
chemotherapy plus immunotherapy, and chemoradiation plus immunotherapy compared to
their counterparts without immunotherapy.
Nonetheless, in this study, a robust analysis of the impact of the timing of
immunotherapy with surgery on the OS of PC patients who received definitive surgery of the
pancreatic tumor using the NCDB was performed. The NCDB is the largest cancer database in
the world which captures the majority of the annual cancer cases diagnosed in the U.S. It serves
as an outstanding source for the investigation of the impact of novel cancer treatments on the
OS of cancer patients

Conclusions
No difference in the OS between patients who received neoadjuvant immunotherapy
and those who receive adjuvant immunotherapy was noticed. However, in the univariate
analysis, neoadjuvant immunotherapy was associated with significantly improved OS compared
to no immunotherapy. The findings warrant future studies with a large sample size for both
neoadjuvant and adjuvant treatment comparisons of immunotherapy.
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Table 16. Baseline characteristics of neoadjuvant vs. adjuvant immunotherapy
Variable

Neoadjuvant immunotherapy

Adjuvant immunotherapy

Total 526

P

408 (77.57%)

118 (22.43%)

61.57

62.20

62.00 (29-88)

0.54

Male

238 (58.33)

62 (52.54)

300 (57.03)

Female

170 (41.67)

56 (47.46)

226 (42.97)

0.26

White

359 (90.43)

113 (96.58)

472 (91.83)

0.049

Black

21 (5.29)

4 (3.42)

25 (4.86)

Other

17 (4.28)

0 (0.00)

17 (3.31)

Unknown

11

1

12

>=13% HG

112 (27.72)

29 (24.58)

141 (27.01)

<13%

292 (72.28)

89 (75.42)

381 (72.99)

Unknown

4

0

4

>=$35,000

292 (72.28)

89 (75.42)

381 (72.99)

<35,000

112 (27.72)

29 (24.58)

141 (27.01)

Unknown

4

0

4

Urban

384 (98.71)

115 (99.14)

499 (98.81)

Rural

5 (2.29)

1 (0.86)

6 (1.19)

Unknown

19

2

21

Academic

318 (78.91)

95 (82.61)

413 (79.73)

Community

85 (21.09)

20 (17.29)

109 (20.27)

Age at diagnosis (mean)
Sex

Race

Education

Income

Place of Living

Hospital Type

0.50

0.50

0.71

0.38
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Unknown

5

3

8

Insured

398 (98.51)

118 (100.00)

516 (98.85)

Not insured

6 (1.49)

0 (0.00)

6 (1.15)

Unknown

4

0

4

Charlson/Deyo

0

303 (74.26)

88 (74.58)

391 (74.33)

Score

1

89 (21.81)

25 (21.19)

114 (21.67)

>=2

16 (3.92)

5 (4.24)

21 (3.99)

0.98

2004-2010

238 (58.33)

40 (33.90)

278 (52.85)

0.0001

2011-2016

170 (41.67)

78 (66.10)

248 (47.15)

Insurance Status

Year of Diagnosis

0.18

Table 17. Univariate and multivariate Cox regression analysis of neoadjuvant immunotherapy vs. adjuvant immunotherapy
Variable

Immunotherapy

N (%)

Univariable analysis

Multivariable analysis

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

0.703

1.06 (0.79-1.41)

0.71

Neoadjuvant immunotherapy

408 (77.57)

1.06 (0.80-1.39)

Adjuvant immunotherapy

118 (22.43)

Ref

Ref

The multivariable analysis was adjusted for the age of diagnosis, sex, race, income, education, place of living, treatment facility type,
insurance status, comorbidity score, and year of diagnosis
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Table 18. Cox regression analysis of only neoadjuvant immunotherapy combinations
Variable

N (%)

Univariable analysis

Multivariable analysis

Hazard Ratio (95% CI)
Immunotherapy

CTx plus immunotherapy

CTxRT plus immunotherapy

Neoadjuvant immunotherapy

373 (1.09)

0.88 (0.78-0.98)

No immunotherapy

33,921 (98.91)

Ref

Neoadjuvant CTx plus imm

95 (0.53)

0.84 (0.65-1.07)

Adjuvant CTx only

17,868 (99.47)

Ref

Neoadjuvant CTxRTx plus imm

258 (1.64)

0.90 (0.78-1.03)

Adjuvant CTxRTx only

15,466 (98.36)

Ref

P

Hazard Ratio
(95% CI)
0.026 0.93 (0.82-1.05)

P
0.220

Ref
0.15

0.93 (0.73-1.20)

0.57

0.12

0.94 (0.81-1.09)

0.43

CTx= chemotherapy CTxRTx=chemoradiation therapy imm=immunotherapy

Table 19. Cox regression analysis of only adjuvant immunotherapy combinations
Variable

Immunotherapy

CTx or CTxRTx plus
immunotherapy

N (%)

Univariable analysis

Multivariable analysis

Hazard Ratio (95% CI)

P
0.91

Adjuvant immunotherapy

106 (0.96)

0.98 (0.76-1.28)

No immunotherapy

10,950 (99.04)

Ref

Adjuvant CTx or CTxRTx plus imm

90 (0.88)

0.97 (0.73-1.30)

Adjuvant CTx or CTxRTx

10,104 (99.12)

Ref

Hazard Ratio (95%
CI)
1.00 (0.76-1.32)

P
0.99

Ref
0.85

1.01 (0.75-1.37)
Ref

We combined adjuvant chemotherapy plus immunotherapy with adjuvant chemoradiation plus immunotherapy due to a small sample
size. When analyzed separately, the results were the same.

0.94
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Figure 5: Overall survival of resectable PDAC patients for neoadjuvant immunotherapy (red) vs.
adjuvant immunotherapy (blue)

Figure 6a: Overall survival of resectable PDAC patients who received only neoadjuvant therapies
with (blue) or without immunotherapy (red)
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Figure 6b: Overall survival of resectable PDAC patients who received neoadjuvant chemotherapy
with (blue) or without (red) neoadjuvant immunotherapy

Figure 6c: Overall survival of resectable PDAC patients who received neoadjuvant
chemoradiation with (blue ) or without (red) neoadjuvant immunotherapy
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Figure 7a: Overall survival of resectable PDAC patients who received only adjuvant therapies
with (blue) or without ( red) immunotherapy

Figure 7b: Overall survival of resectable PDAC patients who received adjuvant chemotherapy or
chemoradiation with (blue) or without (red) immunotherapy
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Chapter 6
Discussion

Summary
The purpose of this dissertation was to use the NCDB, which captures 70% or more of
newly diagnosed cancer cases nationwide to perform a robust analysis to investigate the impact
of immunotherapy in the OS of PDAC patients. The overall goal of this research was to
understand the potential role of immunotherapy in PC survival and determine how best to
incorporate immunotherapy into the current standard-of-care PC treatment paradigms. The
central hypothesis was that immunotherapy will improve the survival of patients with either
resectable or unresectable PDAC and that combining immunotherapy with other treatments
may differentially alter the effect of immunotherapy on patient outcomes. We conducted four
studies to answer the research questions related to the specific aims of this dissertation, the
findings of which are summarized here.
Manuscript 1: The impact of immunotherapy on the survival of pancreatic adenocarcinoma
patients who do not receive definitive surgery of the tumor
Specific aim 1a: Identify the patients and disease characteristics associated with the use of
immunotherapy in unresectable PDAC
Hypothesis: Certain patient and tumor-related factors are associated with the receipt of
immunotherapy
In the multivariable logistic regression analysis treatment at an academic hospital,
having a high school degree, and having insurance were positively associated with receiving
immunotherapy. These patients were more likely to receive immunotherapy compared to their
counterparts. For example, patients who were treated at the non-academic hospital were 62%
(OR: 0.38, CI: 0.33-0.45) less likely to receive immunotherapy compared to patients treated at
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an academic hospital (Table 4). Patients who did not have a high school degree were 23% (OR:
0.77, CI: 0.66-0.90) less likely to receive immunotherapy compared to patients who had a high
school degree. Patients who did not have health insurance were 56% (OR: 0.44, CI: 0.27-0.78)
less likely to receive immunotherapy compared to patients who had insurance (Table 4). These
findings are critical in terms of access to care, improving awareness about decision making, and
improving the education and learning experience of oncologists at non-academic hospitals.
Specific aim 1b: Evaluate the impact of immunotherapy in combination with other standard-ofcare treatments on the survival of unresectable PDAC patients
Hypothesis: Combining immunotherapy with RT, chemotherapy, and chemoradiation
has a superior impact on OS than these treatments without immunotherapy in unresectable PC
A multivariable analysis was performed to compare the survival outcomes of PDAC
patients without surgery who received chemotherapy with and without immunotherapy and
those who received chemoradiation with and without immunotherapy. The analysis
demonstrated that adding immunotherapy to either chemotherapy or chemoradiation therapy
led to a significant OS benefit in both univariate and multivariable Cox regression analysis (Table
6). What is unique about the findings of this study was that chemoradiation plus
immunotherapy was associated with a significantly improved OS, which to our knowledge, has
not been investigated yet. The findings of this study, together with early results of some clinical
trials, warrant future large phase III clinical trials of immunotherapy combined with
chemotherapy or chemoradiation in PAD patients who did not receive definitive surgery of the
pancreatic tumor.
Manuscript 2: The impact of immunotherapy on the survival of pancreatic adenocarcinoma
patients who received definitive surgery of the pancreatic tumor

104
Specific Aim 2a: Identify the predictors of receiving immunotherapy in resectable PDAC patients
Hypothesis: Treatment facility type and socioeconomic status are associated with the use of
immunotherapy
In the multivariable logistic regression analysis, treatment at an academic hospital and
having high school degrees were positively associated with receiving immunotherapy. For
example, patients who were treated in non-academic hospitals were 74% (OR: 0.26, CI: 0.210.32) less likely to receive immunotherapy compared to their counterparts who were treated in
an academic hospital. Patients who did not have a high school degree were 35% (OR: 0.65, CI:
0.54-0.78) less likely to receive immunotherapy compared to patients who had a high school
degree (Table 7). The findings are similar to that of PDAC patients who did not undergo
definitive surgery. These findings are critical for improving access to novel treatments such as
immunotherapy in non-academic health institutions and people who are less educated.
Specific aim 2b: Examined the impact of immunotherapy with other standard-of-care
treatments on the survival of resectable PDAC
Hypothesis: Combining immunotherapy with RT, chemotherapy, and chemoradiation has a
superior impact on OS than these treatments without immunotherapy in resectable PC
In one of the first and largest studies with a robust analysis using the NCDB, the impact
of immunotherapy in combination with chemotherapy, RT, and chemoradiation on the OS of
PDAC patients who received definitive surgery of the tumor was investigated. In this study,
combining chemoradiation therapy with immunotherapy was associated with significantly
improved OS of the patients (Table 9). The findings of this study, together with the results of
other previous studies of the use of immunotherapy with other standard-of-care cancer
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treatments in PDAC patients who receive surgery, warrant the need for future clinical trials of
investigating the impact of immunotherapy in this group of patients.
Manuscript 3: The impact of the sequence of immunotherapy on the survival of pancreatic
adenocarcinoma patients: a retrospective analysis of the national cancer database
Specific Aim 3a: Identify the treatment sequence of immunotherapy with other standard-ofcare treatments on the survival of unresectable PDAC patients
Hypothesis: The OS of patients who start immunotherapy within 30 days of RT or chemotherapy
is superior to those who receive the treatments more than 30 days from each other in
unresectable PDAC
In an extensive analysis using the NCDB, the impact of the timing of immunotherapy
with chemotherapy and RT on the OS of PDAC patients who did not receive definitive surgery of
the pancreatic tumor was investigated. There was no significant difference in the OS of patients
who started immunotherapy within 30 days of chemotherapy, patients who started
immunotherapy 31-90 days before chemotherapy, and patients who started immunotherapy
91-180 days before chemotherapy. (Table 12). There was also no difference in the OS of patients
who started immunotherapy within 30 days of RT, patients who started RT > 30 days before
immunotherapy, and patients who began immunotherapy > 30 days before RT (Table 15). These
findings provide insight into the design of future clinical trials of immunotherapy in PDAC.
Future clinical trials may allow the administration of immunotherapy with chemotherapy and RT
regardless of the treatment sequence.
Manuscript 4: The impact of neoadjuvant and adjuvant immunotherapy on the survival of
pancreatic cancer patients: a retrospective analysis
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Specific Aim 3b: Identify the treatment sequence of immunotherapy with other standard-ofcare treatments on the survival of resectable PDAC patients
Hypothesis: The OS of resectable PDAC patients who receive neoadjuvant immunotherapy is
better than the OS patients who receive adjuvant immunotherapy
The OS between patients who received neoadjuvant immunotherapy and patients who
received adjuvant immunotherapy was compared. There was no significant difference in the
median OS of patients who received neoadjuvant immunotherapy compared to patients who
received adjuvant immunotherapy (Table 17). In the adjuvant subset analysis, immunotherapy
combined with chemotherapy or chemoradiation therapy was not associated with improved OS
compared to chemotherapy or chemoradiation without immunotherapy (Table 19). The findings
warrant future studies with a large sample size for both neoadjuvant and adjuvant treatment
comparisons of immunotherapy in PDAC patients who receive definitive surgery of the
pancreatic tumor.

Implications
This research is the most extensive and robust analysis that has used the NCDB and
investigated the impact of immunotherapy on the OS of PDAC patients. The findings of the first
study indicated that PDAC patients who were treated in an academic hospital and patients who
had a high school degree were more likely to receive immunotherapy compared with their
counterparts. This is important, especially that we found that immunotherapy is associated with
significantly improved OS compared to no immunotherapy. The issue of access to healthcare,
and the utilization of novel treatments by patients need to be addressed. Physicians and
oncologists at nonacademic hospitals may need the training to get familiar with academic
research and provide patients with the most up to date treatment options. In the current study,
immunotherapy combined with chemotherapy and chemoradiation therapy was associated with
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improved OS compared to these treatments without immunotherapy in PDAC patients who did
not receive definitive surgery of pancreatic cancer.
In PDAC patients who received definitive surgery of the pancreatic tumor,
immunotherapy combined with chemoradiation therapy was associated with improved OS
compared to chemoradiation alone. These findings indicate the potential role of
immunotherapy in combination with the current standard-of-care treatments in PDAC patients.
The current study is the most extensive study with a robust analysis that investigated the impact
of immunotherapy on the OS of PDAC patients in combination with other cancer treatments.
The majority of previous studies that reported negative results were based on a small number of
patients and included heavily pre-treated PDAC patients. The findings warrant future clinical
trials of immunotherapy combined with chemotherapy, radiation therapy, and chemoradiation.
In the current research, we found that immunotherapy may interact differently with
chemotherapy and chemoradiation in PDAC patients who receive surgical resection of the
pancreatic tumor and patients who do not undergo surgical resection. Immunotherapy
combined with chemotherapy alone or chemoradiation was associated with improved OS
compared to chemotherapy without immunotherapy or chemoradiation without chemotherapy
in patients who did not receive surgical resection. In patients who underwent surgical resection
of the pancreatic tumor, immunotherapy was only associated with the improved OS when
combined with chemoradiation but not chemotherapy. This is very critical for the design of
future clinical trials of immunotherapy in PDAC, especially that immunotherapy interacts
differently with chemotherapy in patients who receive surgery and in patients who do not
undergo surgery of the pancreatic tumor. Future clinical trials that are investigating the impact
of immunotherapy in the OS of PDAC patients with chemotherapy may need to separate
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patients by surgical status as the two groups responded differently to immunotherapy in our
study.
The mechanism of the immunostimulatory effect of chemotherapy is different in
patients who receive surgery and patients who did not receive surgery and is a possible reason
for the difference in the interaction of immunotherapy with chemotherapy in these two groups
of patients. In PDAC patients who undergo surgical resection of the pancreatic tumor, the
immunostimulatory effect of chemotherapy, especially in the adjuvant setting is through the
inhibition of T regulatory cell and MDSCs rather than the stimulation and increase of T cells. The
increase and stimulation of T cells are significant for immunotherapy to deliver optimal survival
benefits. In patients who do not receive surgery, the stimulatory effect of chemotherapy is
mainly through the stimulation and increase of T cells, which may be one of the reasons
immunotherapies are associated with the improved OS when combined with chemotherapy.
Another critical point to be noticed for the design of the future clinical trials is the
synergetic interaction of immunotherapy with chemoradiation in both patients who receive
surgical resection and patients who do not undergo surgical resection of the pancreatic tumor. A
synergetic interaction with a comparable and improved OS outcome may be achieved in these
groups if both systemic and local immune response is produced. Chemotherapy induces a
systemic immune response, and RT mainly induces a local immune response. Immunotherapy
can work in a synergetic way with systemic and local immune responses and deliver optimal
results. The findings indicate that an aggressive multimodality treatment approach is required to
achieve the maximum benefit of immunotherapy in PDAC patients. The combination of
immunotherapy and chemoradiation has not been studied yet, and the findings of the current
study provide a glimpse of hope and foundation for future clinical trials to consider this
combination while also keeping in mind the life expectancy and treatment toleration of patients.
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The improved OS associated with the use of immunotherapy in combination with
chemoradiation, especially in PDAC patients who received surgical resection of the tumor is
critical. The use of immunotherapy in PDAC has been mainly in a metastatic setting. However,
the findings of our study, together with some studies conducted in non-small cell lung cancer,
provide some evidence that immunotherapy may be beneficial in resectable cancers. Future
clinical trials can use these findings as initial evidence for investigating the efficacy and survival
benefit of immunotherapy in combination with chemoradiation in early-stage or resectable
PDAC. Trials of immunotherapy in resectable PDAC may be even more critical as the majority of
patients eventually succumb to the disease due to the widespread of micrometastases that
happen early in the disease. Immunotherapy may be an excellent therapeutic option for
shrinking the tumor and eliminating occult micrometastases before surgery or eliminating occult
micrometastases after the removal of cancer.
The findings of this dissertation can also be beneficial for the designs of the future
clinical trials of immunotherapy that are investigating the treatment sequence of
immunotherapy with chemotherapy and RT both in resectable and unresectable PDAC. In PDAC
patients with no surgery, there was no difference in the OS of patients who started
immunotherapy and chemotherapy or RT within 30 days of each other, and > 30 days of each
other. There was also no difference in the OS of patients who received neoadjuvant
immunotherapy compared to adjuvant immunotherapy. These findings are essential for future
trials. This is critical as so far; there is no data available that favors a specific treatment
sequence. The majority of the ongoing clinical trials assume that the concurrent use of
immunotherapy with chemotherapy or radiation therapy is better than the sequential.
Another vital element of the findings of the current research is the pattern of care in the
context of immunotherapy. The results indicated a significant difference in the probability of
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receiving immunotherapy for certain groups in both resectable and unresectable PC. Female
sex, Black race, living in an area with high education level, and receiving treatment at
community hospitals were all negatively associated with receiving immunotherapy. It is
significantly crucial given that immunotherapy was associated with improved OS in PDAC
patients. These groups need to be targeted from the perspective of improving access to care
and improving OS. Patients who did not receive surgical resection of the pancreatic tumor and
treated at non-academic hospitals were 74% less likely to receive immunotherapy and 20%
more likely to die compared to their counterparts who were treated at academic hospitals.
Patients who underwent surgery of the tumor and were treated at non-academic hospitals were
62% less likely to receive immunotherapy and 17% more likely to die. This is an example of a
lack of access to novel treatments translated to the disparity in the OS. Several factors may
contribute to the survival disparity in these patients, and treatment at a non-academic hospital
is one of the contributing factors.
Our findings also showed a trend toward some specific treatment patterns in combining
immunotherapy with chemotherapy or RT. In PDAC patients who did not receive surgical
resection of the pancreatic tumor, 88% of the patients started immunotherapy and
chemotherapy with 30 days of each other, indicating a tendency of clinicians to recommend
starting the two treatments close to each other. Among these patients, 76% of the patients
began immunotherapy and chemotherapy on the same day, with 89% of the patients starting
the two treatments within a week of each other. More than 63% of these patients were treated
at academic hospitals. More than 46% of the patients who started chemotherapy and
immunotherapy within 30 days of each other were diagnosed in 2011 or after, while 63% and
84% of the patients who started immunotherapy 31-90 days before chemotherapy and patients
who started immunotherapy 91-180 days before chemotherapy were diagnosed in 2011 or
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after. This indicates a trend toward starting immunotherapy before chemotherapy in recent
years, however, the sample size for these two categories was small.
The sequence of immunotherapy with RT followed the same pattern. More than 78% of
the patients received RT and immunotherapy within 30 days of each other. In the remaining
patients, 15% started RT > 30 days before immunotherapy, and 6% started immunotherapy > 30
days before RT. Among those who began RT and immunotherapy within 30 days of each other,
60% started the two treatments on the same day, with 86% of the patients starting the two
treatments within a week of each other. Among patients who began RT and immunotherapy
within 30 days of each other, 78% were treated at academic hospitals, much higher than the
proportion of patients who received chemotherapy and immunotherapy within 30 days of each
other and were treated at academic hospitals (63%). Only a small percentage (16%) of the
patients who started RT and immunotherapy within 30 days of each other were diagnosed in
2011 or after, while 84% of the patients who received Rt > 30 days before immunotherapy and
60% of patients who received immunotherapy > 30 days before RT were diagnosed in 2011 or
after. These findings provide some indications that in recent years more patients are starting to
take immunotherapy with chemotherapy within 30 days of each other (46%) compared to
starting RT and immunotherapy within 30 days of each other.
In PDAC patients who received surgical resection of the pancreatic tumor, 78% of them
received neoadjuvant immunotherapy compared to the 22% who received adjuvant
immunotherapy. Among those who received neoadjuvant immunotherapy, 41% were diagnosed
in 2011 or after, while among those who received adjuvant immunotherapy, 66% were
diagnosed in 2011 or after that. It indicates that the majority of the patients diagnosed in recent
years received adjuvant immunotherapy. The proportions of patients who received neoadjuvant
or adjuvant immunotherapy and were treated at academic hospitals were the same (79% vs.
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82%). An important take away from the treatment sequence patterns is that the majority of the
patients who received neoadjuvant immunotherapy and started immunotherapy within 30 days
of the start of chemotherapy or RT were diagnosed in 2010 or before, opposite to our
assumption. We observed a trend and noticed that most patients diagnosed in 2010 or before
received neoadjuvant immunotherapy and started immunotherapy within 30 days of starting
chemotherapy or RT.

Limitations
The strength of the current research is the large sample size of the study. The study
used the world’s largest cancer database to investigate the impact of immunotherapy on the OS
of PDAC patients. With a large sample size, we were able to adjust for some important patient
and tumor characteristics. The large sample size also allowed to stratify the study by patients
who received definitive surgery of pancreatic cancer and patients who did not undergo
definitive surgery of pancreatic cancer. However, this research has several limitations. The
limitations are mostly inherent to NCDB, which include incomplete data and ascertainment bias,
lack of data about the cause of death, lack of detailed information on the use of multi-agent
chemotherapy regimens, and lack of information on the type of immunotherapy and if a single
or combined immunotherapy was used. For example, the NCDB does not collect information if a
checkpoint inhibitor or vaccine therapy was given to the patients.
Only a small percentage of the patients received immunotherapy, which indicates that
patients who received immunotherapy represent a particular cohort. These patients may have
characteristics that are different from the rest of the cohort, and the findings may be biased. It is
also possible that these patients have some other confounding characteristics that we were not
able to account for in the NCDB database. It is also possible that the PDAC patients who received
immunotherapy were positive for microsatellite-instability status who responds better to
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immunotherapy compared to other patients. The NCDB does not provide data on the
microsatellite-instability status for PDAC patients. However, testing for microsatellite-instability
status is not part of the routine clinical test of PDAC patients. There was not enough sample size
for the analysis of comparing the impact of RT plus immunotherapy vs. RT alone.

Future Directions
The current retrospective analysis provided the most extensive research about the
impact of immunotherapy on the OS of PDAC patients stratified by definitive surgery of
pancreatic cancer. This research used the NCDB, which is the best resource for cancer research
outside of the multi-institutional clinical trials. The findings provide insights about the potential
role of immunotherapy in the OS of PDAC patients. The findings also provide information about
access to novel treatments and patterns of care. The results of this study warrant future clinical
trials of immunotherapy in PDAC. The clinical trials should be stratified by the definitive surgery
of pancreatic cancer as the interaction of immunotherapy with chemotherapy and
chemoradiation was different in patients who received surgery and in those who did not
undergo surgery. The unique finding in the current study was that combining immunotherapy
with chemoradiation therapy is associated with improved OS compared to chemoradiation
alone in both patients who did not receive definitive surgery and patients who received
definitive surgery of pancreatic cancer. Future clinical trials need to focus on this finding,
especially in resectable PDAC. Immunotherapy has been used mainly in the metastatic setting,
but recent research, including the results of the current study, provide some evidence that it
may work in resectable PDAC.
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Supplemental Tables

Supplemental Table 1. The odds ratio for logistic original and bootstrap models in PDAC patients
who did not receive surgery of the pancreatic tumor
Variables

Original Model
Odds Ratio
(OR)

Age
Sex
Race

Insurance
Dscore

Male
Female
White
Black
Non-White nonBlack
Yes
No
0
1

0.97
Ref
0.94
Ref
0.65
1.12
Ref
0.49
Ref
0.76

Bootstrap
Model
Odds Ratio (OR)

P

0.97
Ref
0.93

0.0001

0.65
1.14

0.0008
0.51

0.49
Ref
0.76

0.009

0.35

0.003
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Place of living
Hospital type
Income
Education
Year of diagnosis

2
Urban
Rural

0.59
Ref
1.18

0.59
Ref
1.20

Academic
Community
>=$35,000
<$35,000
<13% No HSD
>=13% No HSD
2004-2010
2011-2016

Ref
0.38
Ref
0.95
Ref
0.79
Ref
1.04

Ref
0.38
Ref
0.95
Ref
0.79
Ref
1.04

0.002
0.53
0.0001
0.54
0.007
0.63

Chemotherapy

Yes
Ref
Ref
No
0.10
0.10
0.0001
RT
Yes
Ref
Ref
No
0.59
0.59
0.0001
P: The P-value is for the comparison of the odds ratio between the categories of each variable
for the original model not for the comparison of OR between the original model and the
bootstrap model

Supplemental Table 2. The hazard ratio of the original and bootstrap model for (immunotherapy
no vs. yes) in PDAC patients who did not receive surgery of the pancreatic tumor
Variables

Original Model

Bootstrap Model

Hazard Ratio (HR)

Hazard Ratio (HR)

1.01

1.01

Male

Ref

Ref

Female

0.94

0.94

0.0001

White

Ref

Black

0.99

0.99

0.66

Non-White
non-Black

0.88

0.88

0.0001

Yes

Ref

Ref

No

1.06

1.06

0

Ref

Ref

1

1.12

1.12

0.0001

2

1.35

1.35

0.0001

Age
Sex

Race

Insurance

Dscore

P

0.0001

0.0001
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Place of living

Hospital type

Income

Education

Year of diagnosis

Chemotherapy

RT

Immunotherapy

Urban

Ref

Ref

Rural

1.04

1.04

Academic

Ref

Ref

Community

1.21

1.20

>=$35,000

Ref

Ref

<$35,000

1.06

1.06

<13% No HSD

Ref

Ref

>=13% No HSD

0.99

0.99

0.0001

2004-2010

1.14

1.14

0.0001

2011-2016

Ref

Ref

Yes

Ref

Ref

No

1.85

1.85

Yes

Ref

Ref

No

1.41

1.41

Yes

0.88

0.88

No

Ref

0.033

0.0001

0.0001

0.0001

0.0001

0.008

Supplemental Table 3. The hazard ratio of the original and bootstrap model for (chemotherapy
plus immunotherapy vs. chemotherapy alone) in PDAC patients who did not receive surgery of
the pancreatic tumor
Variables

Original
Model

Bootstrap
Model

Hazard Ratio
(HR)

Hazard Ratio
(HR)

1.01

1.01

Male

Ref

Ref

Female

0.93

0.93

0.0001

White

Ref

Black

0.97

0.97

0.017

Age
Sex

Race

P

0.0001
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Insurance

Dscore

Place of living

Hospital type

Income

Education

Year of diagnosis

Chemoimmunotherapy
combination

Non-White nonBlack

0.88

0.88

0.0001

Yes

Ref

Ref

No

1.13

1.13

0

Ref

Ref

1

1.09

1.09

0.0001

2

1.27

1.27

0.0001

Urban

Ref

Ref

Rural

1.04

1.04

Academic

Ref

Ref

Community

1.23

1.23

>=$35,000

Ref

Ref

<$35,000

1.06

1.06

<13% No HSD

Ref

Ref

>=13% No HSD

1.01

1.01

0.26

2004-2010

1.31

1.31

0.0001

2011-2016

Ref

Ref

Chemotherapy plus
immunotherapy

0.86

0.86

Chemotherapy

Ref

0.0001

0.20

0.0001

0.0001

0.003

Supplemental Table 4. The hazard ratio of the original and bootstrap model for (chemoradiation
plus immunotherapy vs. chemoradiation alone) in PDAC patients who did not receive surgery of
the pancreatic tumor
Variables

Age
Sex

Male

Original Model

Bootstrap
Model

Hazard Ratio
(HR)

Hazard Ratio
(HR)

1.01

1.01

Ref

Ref

P

0.0001
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Race

Insurance

Dscore

Place of living

Hospital type

Income

Education

Year of diagnosis

Chemoimmunotherapy
combination

Female

0.97

0.97

0.031

White

Ref

Black

0.93

0.93

0.0001

Non-White nonBlack

0.93

0.94

0.076

Yes

Ref

Ref

No

1.04

1.04

0

Ref

Ref

1

1.10

1.10

0.0001

2

1.19

1.19

0.0001

Urban

Ref

Ref

Rural

1.10

1.10

Academic

Ref

Ref

Community

1.16

1.16

>=$35,000

Ref

Ref

<$35,000

1.10

1.10

<13% No HSD

Ref

Ref

>=13% No HSD

1.10

1.10

0.001

2004-2010

1.34

1.34

0.0001

2011-2016

Ref

Ref

Chemotherapy plus
immunotherapy

0.80

0.81

Chemotherapy

Ref

0.40

0.034

0.0001

0.0005

0.002

Supplemental Table 5. Concordance Index of models for PDAC patients who did not receive
definitive surgery of the pancreatic tumor
Variables

Original Model

Bootstrap Model

Concordance Index
Bias

150

Logistic regression analysis
Cox analysis immunotherapy
Yes vs. No
Cox analysis chemo plus
immunotherapy
Cox analysis chemoradiation
plus immunotherapy

Concordance
Index
0.81
0.685

Concordance
Index
0.81
0.685

0.000
0.000

0.572

0.572

0.000

0.566

0.567

0.001

Supplemental Table 6. The odds ratio for logistic original and bootstrap models in PDAC patients
who received surgery of the pancreatic tumor
Variables

Original Model

Bootstrap Model

Odds Ratio (OR)

Odds Ratio (OR)

0.97

0.97

Male

Ref

Ref

Female

0.83

0.84

0.031

White

Ref

Black

0.48

0.85

0.0003

Non-White nonBlack

0.86

0.87

0.53

Yes

Ref

No

0.50

0.51

0.074

0

Ref

Ref

1

0.74

0.74

0.004

2

0.54

0.55

0.004

Urban

Ref

Ref

Rural

0.43

0.44

Academic

Ref

Ref

Community

0.26

0.26

>=$35,000

Ref

Ref

<$35,000

0.86

0.86

Age
Sex

Race

Insurance

Dscore

Place of living

Hospital type

Income

P

0.0001

0.099

0.0001

0.16
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Education

<13% No HSD

Ref

Ref

>=13% No HSD

0.71

0.71

0.002

Year of
diagnosis

2004-2010

1.27

1.27

0.005

2011-2016

Ref

Ref

Chemotherapy

Yes

Ref

Ref

No

0.21

0.21

Yes

Ref

Ref

No

0.35

0.35

RT

0.0001

0.0001

Supplemental Table 7. The hazard ratio of the original and bootstrap model for (immunotherapy
no vs. yes) in PDAC patients who received surgery of the pancreatic tumor
Variables

Original Model

Bootstrap Model

Hazard Ratio
(HR)

Hazard Ratio (HR)

1.01

1.01

Male

Ref

Ref

Female

0.92

0.92

0.0001

White

Ref

Black

1.04

1.04

0.022

Non-White nonBlack

0.87

0.87

0.0001

Yes

Ref

Ref

No

1.07

1.08

0

Ref

Ref

1

1.06

1.06

0.0001

2

1.23

1.23

0.0001

Urban

Ref

Ref

Age
Sex

Race

Insurance

Dscore

Place of living

P

0.0001

0.039
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Hospital type

Income

Education

Year of diagnosis

Chemotherapy

RT

Immunotherapy

Rural

1.05

1.05

0.16

Academic

Ref

Ref

Community

1.21

1.21

>=$35,000

Ref

Ref

<$35,000

1.09

1.09

<13% No HSD

Ref

Ref

>=13% No HSD

1.07

1.07

0.0001

2004-2010

1.16

1.16

0.0001

2011-2016

Ref

Ref

Yes

Ref

Ref

No

1.13

1.13

Yes

Ref

Ref

No

1.06

1.06

0.0001

Yes

0.90

0.90

0.038

No

Ref

Ref

0.0001

0.0001

0.0001

Supplemental Table 8. The hazard ratio of the original and bootstrap model for (chemotherapy
plus immunotherapy vs. chemotherapy alone) in PDAC patients who received surgery of the
pancreatic tumor
Variables

Original
Model

Bootstrap
Model

Hazard Ratio
(HR)

Hazard Ratio
(HR)

1.01

1.01

Male

Ref

Ref

Female

0.95

0.95

0.002

White

Ref

Black

1.09

1.09

0.008

Age
Sex

Race

P

0.0001
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Insurance

Dscore

Place of living

Hospital type

Income

Education

Year of diagnosis

Chemoimmunotherapy
combination

Non-White non-Black

0.91

0.91

0.055

Yes

Ref

Ref

No

0.93

1.93

0

Ref

Ref

1

1.07

1.07

0.0007

2

1.19

1.18

0.0001

Urban

Ref

Ref

Rural

1.07

1.07

Academic

Ref

Ref

Community

1.22

1.22

>=$35,000

Ref

Ref

<$35,000

1.07

1.08

<13% No HSD

Ref

Ref

>=13% No HSD

1.05

1.05

0.0133

2004-2010

1.20

1.20

0.0001

2011-2016

Ref

Ref

Chemotherapy plus
immunotherapy

0.93

0.93

Chemotherapy

Ref

0.23

0.23

0.0001

0.001

0.48

Supplemental Table 9. The hazard ratio of the original and bootstrap model for (chemoradiation
plus immunotherapy vs. chemoradiation alone) in PDAC patients who received surgery of the
pancreatic tumor
Variables

Age
Sex

Male

Original
Model

Bootstrap
Model

Hazard
Ratio (HR)

Hazard Ratio
(HR)

1.01

1.01

Ref

Ref

P

0.0001
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Race

Insurance

Dscore

Place of living

Hospital type

Income

Education

Year of diagnosis

Chemoimmunotherapy
combination

Female

0.93

0.93

0.0001

White

Ref

Black

0.97

0.97

0.32

Non-White non-Black

0.86

0.86

0.003

Yes

Ref

Ref

No

1.07

1.07

0

Ref

Ref

1

1.07

1.08

0.0002

2

1.19

1.19

0.0001

Urban

Ref

Ref

Rural

1.02

1.02

Academic

Ref

Ref

Community

1.15

1.15

>=$35,000

Ref

Ref

<$35,000

1.07

1.07

<13% No HSD

Ref

Ref

>=13% No HSD

1.08

1.08

0.0002

2004-2010

1.17

1.18

0.0001

2011-2016

Ref

Ref

Chemotherapy plus
immunotherapy

0.85

0.85

Chemotherapy

Ref

0.25

0.80

0.0001

0.001

0.005

Supplemental Table 10. Concordance Index of models for PDAC patients who received definitive
surgery of the pancreatic tumor
Variables

Original Model

Bootstrap Model

Concordance
Index

Concordance
Index

Concordance Index
Bias
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Logistic regression analysis
Cox analysis immunotherapy
Yes vs. No
Cox analysis chemo plus
immunotherapy
Cox analysis chemoradiation
plus immunotherapy

0.799
0.587

0.801
0.587

0.002
0.000

0.558

0.558

0.000

0.557

0.557

0.000

